Thiolated-polymer-based nanoparticles as an avant-garde approach for anticancer therapies—Reviewing thiomers from chitosan and hyaluronic acid by Grosso, Roberto & Paz Báñez, María Violante de
pharmaceutics
Review
Thiolated-Polymer-Based Nanoparticles as an Avant-Garde
Approach for Anticancer Therapies—Reviewing Thiomers
from Chitosan and Hyaluronic Acid
Roberto Grosso and M.-Violante de-Paz *


Citation: Grosso, R.; de-Paz, M.-V.
Thiolated-Polymer-Based
Nanoparticles as an Avant-Garde
Approach for Anticancer
Therapies—Reviewing Thiomers
from Chitosan and Hyaluronic Acid.
Pharmaceutics 2021, 13, 854. https://
doi.org/10.3390/pharmaceutics13060854
Academic Editor: Franco Dosio
Received: 14 May 2021
Accepted: 5 June 2021
Published: 8 June 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
Departamento Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad de Sevilla,
41012 Sevilla, Spain; robgrobul@alum.us.es
* Correspondence: vdepaz@us.es
Abstract: Thiomers (or thiolated polymers) have broken through as avant-garde approaches in anti-
cancer therapy. Their distinguished reactivity and properties, closely linked to their final applications,
justify the extensive research conducted on their preparation and use as smart drug-delivery systems
(DDSs). Multiple studies have demonstrated that thiomer-rich nanoformulations can overcome major
drawbacks found when administering diverse active pharmaceutical ingredients (APIs), especially in
cancer therapy. This work focuses on providing a complete and concise review of the synthetic tools
available to thiolate cationic and anionic polymers, in particular chitosan (CTS) and hyaluronic acid
(HA), respectively, drawing attention to the most successful procedures. Their chemical reactivity
and most relevant properties regarding their use in anticancer formulations are also discussed. In
addition, a variety of NP formation procedures are outlined, as well as their use in cancer therapy,
particularly for taxanes and siRNA. It is expected that the current work could clarify the main
synthetic strategies available, with their scope and drawbacks, as well as provide some insight into
thiomer chemistry. Therefore, this review can inspire new research strategies in the development of
efficient formulations for the treatment of cancer.
Keywords: thiomers; thiolated polymers; chitosan; hyaluronic acid; anticancer therapy; nanofor-
mulations; nanotechnology; siRNA; taxanes; thiolation; preactivated; EPR effect; mucoadhesion;
glutathione; smart DDS; permeation enhancer; disulfide bonds
1. Introduction
Cancer is a major public health problem worldwide and is the second-leading cause of
death in developed countries—only exceeded by cardiovascular diseases—which accounts
for more than 8.8 million deaths per year. The lifetime probability of developing an
invasive cancer is currently above 40% for men and close to that for women; in 2020,
1,806,590 new cancer cases and 606,520 cancer deaths were projected to occur in the United
States (Figure 1) [1]. Cancer therapy is dictated by the cancer type, stage at diagnosis, and
the patient’s tolerance to the prescribed therapy [2]. Chemotherapy serves as a method to
block the expansion of growing neoplasm. Its results are enhanced when combined with
other classical anticancer approaches [3]. However, the active pharmaceutical ingredients
(APIs) for the treatment of cancer do not usually differentiate between healthy cells and
cancer cells, as both of them are exposed to the cytotoxic effects of chemotherapeutic
drugs [4]. In addition, cancer treatments generally involve the administration of relatively
high doses of the drug in the hope that a portion, although minor, will go to damaged
tissues [5]. Therefore, it is necessary to explore other therapeutic options that allow the drug
of interest to accumulate in the cancerous tissue while decreasing the adverse reactions
associated with its presence in healthy niches.
Nanotechnology has been extensively investigated for potential applications in the
diagnosis and treatment of cancer, since it offers a suitable means of site-specific and/or
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time-controlled delivery of small- or large-molecular-weight drugs and other bioactive
agents [1–6]. Drug-delivery systems (DDSs) based on polymer NPs have the potential to
improve current disease therapies because of their ability to go through multiple biological
barriers, overcoming the drawbacks of insoluble drugs, whereas their renal clearance will
be reduced [4]. Additional benefits such as an increase in half-life, payload, and suppression
of the side effects of toxic drugs are of great interest. Therefore, nanometric-sized systems
are being studied for their use in either passive or active targeted cancer therapy. In cancer
tissues, there are two relevant parameters that can act as internal stimuli in smart DDSs:
the acidic pH [7,8] and the reductive environment found in tumors [9]. Both have been
vastly explored as internal trigger for the release of payloads.
Figure 1. Estimated number of deaths by the main types of cancer in the United States, for both sexes,
in 2020. Data obtained from [1].
Thiolated polymers (thiomers) are biocompatible polymers that bear free or activated
thiol groups covalently attached to them. They began to be explored in 1999 [10], and
have since been used in multiple biomedical and pharmaceutical applications due to the
close interest in their study among the research community [11–13]. These applications
are connected with the presence of their thiol groups and their capability of conducting
thiol–disulfide exchange reactions and oxidizing to disulfide bridges: from soft-tissue
engineering [14] as biomaterial support for cartilage repair [15] and 3D bioscaffolds for
cell culture [16,17] to antibacterial activity [18–21]. They are also prominent candidates for
the formulation of controlled delivery carriers of APIs, whether for topical use [22], as dry
powder inhalers [23], or in oral administration [24], among others. Their formulations can
enclose small molecules such as methotrexate [25], sodium naproxen [26], isoniazid [23]
docetaxel [27], and paclitaxel [28], as well as hydrophilic macromolecular drugs [29], but
also peptides, RNA, and biomacromolecules like insulin [24], basic fibroblast growth
factors [30], and siRNA [31].
In tackling the preparation of new thiolated polymers, derivatization of (semi)natural
polysaccharides is an interesting approach because of their inherent biocompatibility,
degradability, absence of toxicity, and chemical versatility. Due to their unique properties,
chitosan (CTS) and hyaluronic acid (HA) stand out among the most promising polysac-
charides studied for biomedical applications [11–13,32], and more recently, their thiolated
derivatives are gaining attention. In this review, we will focus on the thiolation strategies
of the major biocompatible polysaccharides CTS and HA as promising platforms for the
development of nanoparticulated DDS in anticancer therapy. In particular, we will discuss
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the main approaches published regarding the delivery of selected anticancer APIs such as
taxanes and siRNAs.
2. Cancer and Nanotechnology
Cancer has been one of the most studied pathologies in modern history. Molecularly,
it is interesting to mention that, as of the year 2000, it was proposed that neoplastic diseases
shared six characteristics that constitute their basic organizing principles, thus providing
a logical framework to understand them even when the diversity among this group of
pathologies is enormous. These peculiarities were baptized as “The Six Hallmarks of
Cancer” (Figure 2a), and the consensus reached at that moment was that as healthy cells
evolve gradually to a cancerous state, they acquire a succession of these hallmark abilities
that allow them to behave as a prototypical tumor. The acquisition of such malignant
properties during multistep tumorigenesis has been concluded to be favored by two
enabling characteristics; that is, phenomena that create the necessary breeding ground for
cancer cells to start developing: genome instability and mutation, and tumor-promoting
inflammation [33].
Figure 2. (a) The six hallmarks of cancer; (b) emerging hallmarks and enabling characteristics.
Reprinted with permission from [33] (Copyright 2011 Elsevier Editorial).
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Therefore, the six hallmarks of cancer can be defined as distinctive and complementary
capabilities that enable tumor growth and metastatic dissemination [33]. They include:
(1) sustaining proliferative signaling, (2) evading growth suppressors, (3) activating inva-
sion and metastasis, (4) enabling replicative immortality, (5) inducing angiogenesis, and (6)
resisting cell death. Nonetheless, an increased body of research during the past decades
has suggested that there are not six hallmarks of cancer, but in fact eight, the list being
completed with (7) deregulating cellular energetics and (8) avoiding immune destruction
(Figure 2b) [33].
As far as cancer therapy is concerned, treatment is dictated by the cancer type, stage
at diagnosis, and the patient’s tolerance to the prescribed therapy [2]. While surgery and
radiotherapy are the primary treatment used for local and nonmetastatic cancers, other
treatments can be employed such as chemotherapy, and hormone and biological therapies.
Thus, for example, in the case of solid tumors, surgery is the local treatment of choice,
as the damage is confined to a limited area of the body. However, most patients require
the combination of two or more therapeutic treatments due to the potential spread of
the disease, as well as to effectively prevent the evolution of the disease from early to
advanced stages. Chemotherapy works by inhibiting the division of rapidly growing cells,
and combined with surgery or radiotherapy, the effectiveness of these treatment modalities
are increased [3].
Although chemotherapy is the main treatment for cancer patients, the active phar-
maceutical ingredients (APIs) used do not differentiate between healthy cells and cancer
cells. Both of them are exposed to the cytotoxic effects of chemotherapeutic drugs, and
consequently, the drugs interfere the growing pattern of normal cells with fast proliferation
rates, such as the hair follicles, and bone marrow and gastrointestinal tract cells, and
provoke long-term toxic effects on the heart, lungs, and kidneys [4]. Typical harmful side
effects associated with chemotherapy, such as nausea, vomiting, immune suppression,
hepatotoxicity, nephrotoxicity, memory loss, anemia, and even death, are rooted in the use
of such nonspecific therapeutic systems.
Therefore, and regarding drug administration, the methods used traditionally have
been limited to making the drug accessible to the bloodstream, relying on the irrigation
and the drug affinity for the tissues for the access to the target. In fact, bioavailability is
still measured from drug levels in the bloodstream, not in the target surroundings. In
many cases, only a small portion of the administered drug reaches the tumor site [6]. As
a consequence, cancer treatments generally involve the administration of relatively high
doses of the drug in the hope that a portion, although minor, will go to damaged tissues [5].
Thus, there is a need to increase the drug concentration in the cancerous tissue while
reducing the side effects associated with chemotherapeutic molecules. This requirement
is even more compelling in the case of highly toxic anticancer drugs, which may also
present physicochemical and stability features that are too deficient. In addition, this
becomes complicated when considering that even when the drug reaches the tumor, cancer
cells can develop drug resistance. For instance, P-glycoprotein (P-gp, where “P” refers to
permeability) has been documented to be overexpressed in various drug-resistant tumors,
thereby enabling direct drug efflux (meaning it works as a drug efflux pump) and limiting
intracellular accumulation of several anticancer agents [34]. Thus, the indiscriminate
destruction of normal cells, the toxicity of conventional chemotherapeutic drugs, as well as
the development of multidrug resistance, support the need of finding new effective targeted
treatments based on the differences found in the molecular biology of the tumor cells.
Significant efforts have been devoted to take advantage of the potentials of nan-
otechnology in drug delivery, since it offers a suitable means of site-specific and/or time-
controlled delivery of small- or large-molecular-weight drugs and other bioactive agents.
Nanotechnology has also been extensively studied for potential applications in the diagno-
sis and treatment of cancer [1–6].
Pharmaceutical nanotechnology focuses on formulating APIs into biocompatible
nanoforms in which the drug is dissolved, entrapped, encapsulated, or attached to a
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nanoparticle matrix. The nanoscale size of these delivery systems is the basis for many
of these advantages. Several types of nanoparticulate systems have been attempted as
potential DDSs, including biodegradable polymeric nanoparticles (NPs), polymeric mi-
celles, solid nanoparticles, lipid-based nanoparticles (e.g., solid lipid nanoparticles (SLNs),
nanostructured lipid carriers (NLCs), and lipid drug conjugates (LDCs)), nanoliposomes,
inorganic nanoparticles, dendrimers, magnetic nanoparticles, ferro-fluids, and quantum
dots [35]. Among the most widely investigated nanocarriers in cancer detection and cancer
therapy are carbon nanotubes, micelles, dendrimers, polymeric nanoparticles, liposomes,
nanoshells, and polymer–drug conjugates/proteins.
Polymer NPs have gained significant attention among the numerous nanotechnology
approaches, as is stressed by the fact that over 90% of the scientific articles published on
cancer therapeutics in the last decade were based on the use of such systems [4]. DDSs
based on polymer NPs have the potential to improve current disease therapies because of
their ability to overcome multiple biological barriers and release a therapeutic molecule
within the optimal dosage range. They are also capable of overcoming the drawbacks
of insoluble drugs. This is the case for anticancer molecules such as camptothecin [7],
doxorubicin [36], and the taxanes paclitaxel [37] and docetaxel [27]. Additional benefits
such as an increase in half-life, payload, and solubility of APIs can be attained. Being
embedded into the nanoplatform conjugate, chemotherapeutic drugs can be transported to
tumors without damaging healthy tissues and, therefore, a drop in their toxicity profile in
the human body is expected to occur.
Consequently, nanometric-sized systems have become the option of choice, and they
are being investigated for their use in either passive (by enhanced permeability and re-
tention) or active (by the functionalization of the surface of the carriers) targeted cancer
therapies. Angiogenesis during tumor growth results in a defective hypervascularization
and a deficient lymphatic drainage system, which has given rise to the concept of passive
targeting of NPs to tumors through the “enhanced permeability and retention” (EPR)
effect [4,38]. Passive tissue targeting uses the increased permeability of tumor vasculature
and the poor lymphatic drainage of tumors (EPR effect; Figure 3) [39], allowing drug-
delivery nanocarriers (cutoff size of >400 nm) to accumulate and diffuse preferentially
in the vicinity of tumors, with the desirable release of the chemotherapeutic agents in
the tumor.
Figure 3. Schematic representation of the passive targeting of nanomedicines (EPR effect) in human tumors. Numbers
represent some major differences found in tumor microenvironments of human cancers in contrast with murine tumors.
Reprinted with permission from [39] (Copyright 2016 Elsevier Editorial).
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However, not only the encapsulation, but also the release of drugs at the target tissue is
vital in drug delivery. By introducing responsive groups, the carrier could release the drug
under specific stimuli. In order to ensure controllable and optimal releasing at desirable
sites, a variety of “stimulus-responsive” nanoparticulated DDSs have been designed [40,41].
Internal (or endogenous) stimulus arises from variation in a target site parameter, such as
relative changes in pH; different expression of a specific enzyme, factors, or other molecules;
and abnormal redox balance [42]. In cancer tissues, there are two relevant parameters that
can act as internal stimuli: the acidic pH and the reductive environment found in tumors.
Thus, compared with healthy tissues, lower pHs (6.2–6.9) of the extracellular matrix have
been found in cancerous cells because of the Warburg effect [43]. The differences in pH
have been vastly explored as an internal trigger for the release of payloads [7,8]. In addition,
pH differences between intracellular endosomes/lysosomes (with pH of 4.0–6.0) of normal
and cancer cells is extraordinary [44]. Redox potential is another internal stimulus for
responsive release of drugs [9].
Glutathione (GSH), a tripeptide constituted by L-γ-glutamyl-L-cysteinyl-glycine, is
involved in the formation and lysis of disulfide bridges; it serves as a general reductant for
cells, and its intracellular concentration is 1–10 mM in mammalian cells [45]. Glutathione
exists in reduced (GSH) and oxidized (glutathione disulfide, GSSG) states, where the
GSH/GSSG system is the major redox couple in animal cells [14]. GSH plays several vital
roles in maintaining the bioactivity of cells, including antioxidation, maintenance of the
redox state, modulation of the immune response, and detoxification of xenobiotics [42].
The ratio of the GSSG/GSH couple can serve as an important indicator of the cellular
redox environment [46]. Intracellular concentration of GSH is hundreds to thousands of
times higher than that in ECM [47], and more importantly, elevated levels of GSH are
found in tumor cells; for example, in bone marrow, breast, colon, larynx, and lung cancers,
to minimize radical damage from oxidative stress [46]. Thus, the disulfide crosslinking
reaction has an advantage in the development of cancer therapies over other chemistries,
since redox potential is an internal stimulus for responsive releasing of delivery system.
With all of this in mind, it is no surprise that thiomers (that is, polymers that have un-
dergone modifications regarding the addition of thiol groups) have broken though as avant-
garde approaches in this field. Several studies agreed that their multiple properties make
them perfect candidates to take part in nanoformulations that act as drug-delivery systems
for compounds with major difficulties in administration, especially in anticancer therapy.
3. Thiomers: Reactivity and Distinguished Properties
Thiolated polymers (thiomers) are macromolecules with free and exposed thiol groups
on the surface of the polymeric backbone, covalently attached by different synthetic routes.
Thiomers came into the research arena in the 1990s [10], and have since found multi-
ple applications. For example, thiomers display a great cation binding capacity [48,49],
demonstrated for metal ions such as Au(III), Pd(II), Pt(IV) [50], As(III), As(V) [51], Hg(II),
Cu(II), and Ni(II) [52], as well as an efficient Pd carrier [53]. They are also of utility in the
fabrication of colorimetric sensors for Hg2+ detection at trace levels [54]. As mentioned
before, thiomers are of special interest in biomedical applications; for example, as 3D
bioscaffolds [14–17]. Some of them exhibit antibacterial activity. Thus, N-acyl thiolated CTS
has demonstrated to be a rewarding target group for highly efficient, biocompatible and
cost-effective antimicrobial compounds [18]. Therefore, the thiolated low-molecular-weight
CTS–thioglycolic acid conjugate (CTS–TGA) was proposed as a promising and effective
broadband antimicrobial compound [21]. In addition, 3D sponges composed of chitosan
thiolated with 11-mercaptoundecanoic acid (CTS–MUA) showed high antibacterial activ-
ity and specificity against Pseudomonas aeruginosa, equivalent to conventional antibiotic
drugs [19]. Such sponges were also relevant as a potential environmental pollution remedi-
ation, since they exhibited high adsorption capacity for methyl orange, the chosen model
organic pollutant [19]. The antibacterial effect of CTS–MUA against Echerichia coli was
confirmed and showed better antibacterial ability than pristine chitosan [20].
Pharmaceutics 2021, 13, 854 7 of 48
Specifically, and due to their exceptional properties, thiomers have shown to be
potentially useful materials for the synthesis of nanostructures specialized in the delivery of
multiple compounds via different routes of administration. As mentioned above, enclosed
molecules vary from peptides or siRNA to some biomacromolecules or hydrophilic drugs.
For example, the use of CTS thiomers for the formation of peptide nanocarriers was
demonstrated by Cheng et al. [55]. The prepared thiolated glycol–CTS succinate formed
ionic complexes with the positively charged melittin, an amphipathic peptide used in cancer
therapy. The dual secured nano-sting (DSNS) was prepared through the combination
of zwitterionic interactions and disulfide bonds. The lethal action of melittin-loaded
DSNS for MCF-7, HCT-116, SKOV-3, and NCI/ADR-RES (multidrug resistant) cancer
cells was confirmed, as the system could kill almost 100% of them without showing any
hemolytic effect.
Before going into the methods for preparing thiomers, their reactivity and properties
are briefly discussed below.
In general terms, thiol groups can react by means of two types of mechanisms: either
nucleophilic or radical mediated reactions, some of which are recorded in Figure 4. As
nucleophilic examples, the thiol–disulfide exchange reaction and Michael reaction are
especially relevant, and the oxidation and radical-initiated thiol–ene click reaction belongs
to those that exhibit a radical mechanism. Thiolate anions (R-S−) are the reactive species
involved in nucleophilic reactions, and hence, the pKa of the thiol moiety is a vital parameter
for these chemical modifications [56,57]. On the other hand, thiyl radicals (R-S•) are the
reactive species in the oxidation of thiol moieties by oxygen, as well as in thermal or
photo-initiated thiol–ene reactions [58].
Figure 4. Selected examples of reactivity of thiomers.
3.1. Thiol Oxidation and Disulfide Bond Formation: In Situ Gelling Properties
One of the reactions in which thiomers intervene, either on purpose or as a side
reaction, is the formation of disulfide bonds. Disulfide linkages play a key role in numerous
properties found for thiolated polymers such as mucoadhesiveness, in situ gelling features,
permeation enhancing, and efflux-pump inhibition [59], and are of particular interest for
bioconjugation [60], controlled drug delivery [26,30,61], and cell encapsulation [16,17,62],
due to the ability of cells to cleave disulfide bonds by secreting natural reductants such
as glutathione.
The preparation of materials with disulfide bonds in their structure can take place by a
radical or nucleophilic mechanism (Figure 4), the first being preferred. Thiol oxidation is a
multistep process that requires the initial formation of thiolate anions (R-S−) that react with
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molecular oxygen to generate the reactive radical species (R-S•) [63]. Thus, the formation
of disulfide bonds by both mechanisms is critically dependent on the acidic character of the
sulfhydryl moiety. Understanding the balance between thiol and thiolate anion residues at
different pHs allows a deeper understanding of such properties.
The ratio of thiols to thiolate anions is governed by the pKa of the sulfhydryl group
so that the lower the pKa, the higher the percentage of R-S− at a fixed pH and, there-
fore, its reactivity. Taking L-cysteine (pKa = 8.0) as an example and according to the
Henderson–Hasselbalch equation (Equation (1)), once pH values pass from pKa-1 (from
pH 7 and above), a significant [R-S−] is found in the medium, and it increases steadily
until the values are close to 100%, when the pH is two units above the value of pKa
(pH = pKa + 2 = 8 + 2 = 10) ratio [(R-S−/R-SH) = 100/1 at pH 10] (Figure 5).





Figure 5. Representation of the concentrations of RSH and RS− (in percentages, calculated from the
Henderson–Hasselbalch equation) for Cys based on its pKa.
Since thiols have a pKa of ∼8–10, this oxidation process is, in general, a very slow
reaction under physiological conditions (pH 7.4). However, the pKa of a thiolated residue
is influenced by neighboring groups, and hence by their incorporation into a polymer
backbone. For example, Bermejo-Velasco et al. [63] have investigated the in situ gelling
properties of HA thiomers, a common feature of thiolated polymers that is linked to
disulfide formation and which can lead to a boost in the mechanical stability of the material.
In general, disulfide bond formation by a radical mechanism does usually require long
periods and is addressed either at basic pH [64], with the consequent increase on [R-S−] in
the media, or using oxidants such as H2O2 or iodine [65,66]. Achieving it at physiological
pH and at a convenient tempo is of great interest for biological applications. Specifically,
they have studied the effect that the presence of substituents in the β-position to the thiol
group in the derivatization residue has in disulfide formation. They demonstrated that
electron-withdrawing groups at the β-position reduced the pKa of the thiol group to 7.0 for
HA-Cys, 7.4 for N-acetylcysteine (HA-NAC), and 8.1 for HA-3-mercaptopropanoic acid
(HA-MPA) derivatives, respectively. Thus, the thiolate anion (R-S−), the concentration
of which controls the kinetics of disulfide formation, would be the predominant species
in the acid–base equilibrium for HA-Cys, and accounts for 50% for HA-NAC at pH 7.4,
in agreement with the Henderson–Hasselbalch equation. It was not surprising that the
authors then found that HA-Cys and HA-NAC formed hydrogels at pH 7.4, with the
procedure being remarkably quicker than the former (3.5 min for HA-Cys compared to
10 h for HA-NAC). The other thiolated polymer, HA-MPA, did not form any gel at pH 7.4
even after 24 h.
When thiol oxidation is a reaction to prevent, it should be taken into account that thio-
lated polymers are susceptible to oxidation in aqueous media at pH > (pKa-2), being more
pronounced at higher pHs [13,63]. This side reaction can be induced by oxygen [16,25,67],
being available in most body fluids and aqueous media, or by oxidizing agents [68]. The
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addition of antioxidants or reducing agents at the end of the thiolation reaction such as
2-mercaptoethan-1-ol [69], dithiothreitol (DTT) [20,30], or tris(2-carboxyethyl)phosphine
(TCEP) [18,70] can cleave/reduce disulfide bond formation.
Another alternative to prepare disulfide linkages is by the thiol–disulfide exchange
reaction (Figure 4). As mentioned above, this is a nucleophilic procedure and is conducted
by the nucleophilic attack of the thiolate anion (R-S−) over an already-formed disulfide
linkage (R’-S-S-R’).
Free thiols from thiomers can be protected while preactivated with a 2-pyridylthio
substructure, such as those derived from 2-mercaptopyridine, 2-mercaptonicotinic acid,
(2-MNA) and 6-mercaptonicotinamide (6-MNAm), with the latter two being preferred to
the former due to safety reasons (Figure 6) [63].
Figure 6. General structure of thiomers with protected-preactivated sulfhydryl groups with 2-
pyridylthio substructure (2-MNA: 2-mercaptonicotinic acid; 6-MNAm: 6-mercaptonicotinamide).
This S-protection not only provides stability for their extemporaneous oxidation, but
also increases their reactivity compared to the unprotected counterparts when they meet
the cysteine-rich subdomains in the human body, thus improving their stability and reactiv-
ity [71]. Consequently, they are known as preactivated thiomers. This augmented reactivity
responds to the electron-withdrawing effect of the π-deficient ring, which promotes the
lysis of asymmetric disulfide linkages, so that the formation of more stable disulfides, with
electron-donating groups, is favorable. Hence, the thioamide 2-mercaptopyridine, 2-MNA,
or 6-MNAm can be easily cleaved off [72].
3.2. Thiol–Ene Reactions
The relatively weak sulfur–hydrogen bonds of thiols, as well as the nucleophilic
nature of thiolate ions (R-S−), are responsible for the participation of thiols in a plethora of
chemical reactions that occur under mild conditions with almost quantitative yields. Two
relevant thiol reactions, which are englobed under the term thiol–ene reactions, describe
the modifications of thiols with a wide variety of unsaturated functional groups: on one
hand, the radical addition of thiol to electron-rich/electron-poor carbon–carbon double
bonds; and on the other, the catalyzed anionic thiol Michael addition to electron-deficient
carbon–carbon double bonds (Figure 4).
Reactions of thiols with enes, whether proceeding through a radical or anionic mecha-
nism, have many of the attributes of click reactions [73], and accordingly, are now routinely
referred to as thiol click reactions in the literature. Among their most outstanding proper-
ties, it is worth mentioning that: (1) they are facile synthetic strategies in which a range of
easily obtainable starting materials participate, many of them being commercially available
(both thiols and enes); (2) they are highly efficient reactions (quantitative conversions),
easy to perform under mild conditions, that do not originate byproducts and display fast
reaction rates; (3) they are tolerant to many different reaction conditions/solvents, for
example, being insensitive to water, and more significantly, to ambient oxygen; (4) they can
be conducted either in bulk or in environmentally benign solvents over a large concentra-
tion range, and only small concentrations of relatively benign catalysts are needed; (5) a
clean-up step is essentially unnecessary; (6) these synthetic processes follow clearly defined
reaction pathways that yield a single regioselective product; and (7) the orthogonality of
the reactions and the compatibility of the processes with numerous functional groups and
biological processes make them especially attractive for biomedical applications.
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Any nonsterically hindered terminal ene can participate in the radical-mediated thiol–
ene process, with electron-rich (vinyl ether) and/or strained enes (norbornene) reacting
more rapidly than electron-deficient enes. The relative reactivities (in order of decreasing
reactivity) of enes toward radical thiol–ene reactions are as follows: norbornenes > vinyl
ethers > methacrylate > acrylonitrile > styrene > maleimides > conjugated dienes [74].
Thiol–ene reactions can be induced by thermal or photochemical initiators (Figure 7a), and
it was found that those using photochemical conditions lead to faster and, in many cases,
quantitative conversions [75]. The ideal thiol–ene radical reaction revolves around the
alternation between the thiyl radical and the carbon-centered radical derived from the ene;
conversions near 100% are achieved, and the net reaction is simply the combination of the
thiol and the ene moieties to render the alkylthioether derivative. When photopolymeriza-
tions based on thiol–ene reactions are conducted, highly uniform polymer networks are
achieved, promoting unique capabilities related to spatial and temporal control of the click
reaction [76]. Photo-initiated thiol–ene reactions are frequently used for the synthesis of
hydrogel networks in the biomedical field [77].
Figure 7. Mechanisms of (a) radical- and (b) nucleophile-initiated thiol–ene additions.
Another interesting nucleophilic reaction in which thiol groups participate is the
Michael addition, commonly used to crosslink thiomers to improve the mechanical prop-
erties of, for example, 3D scaffolds and hydrogels [11,78,79]. It is also of interest in the
anchoring of APIs to DDSs such as the monoclonal antibody Cetuximab [80].
Mercapto groups act as Michael donors and react with activated olefines, namely α,β-
unsaturated carbonyl groups such as maleimides, vinyl sulfones, acrylates, and methacry-
lates (cited from highest to lowest reactivity). The reaction is catalyzed by a nucleophile
(Figure 7) that generates the thiolate anion, which is the nucleophilic species. R-S− will
react with the β carbon from the α,β-unsaturated carbonyl moiety [11,15,78,79]. The cata-
lysts are nucleophilic species such as amines [81] or alkylphosphines [82], which have been
demonstrated to be extremely efficient in speeding up thiol–Michael addition reactions.
3.3. Properties for Biomedical Applications
However, high reactivity of thiol groups does not always correlate with enhanced
physiological properties, such is the case of their mucoadhesion behavior to biological
surfaces like mucins or keratins. It should be considered that free unprotected thiol groups
react with disulfide bonds of proteins by the thiol–disulfide exchange reaction, whereas
S-protected thiol groups react with free thiol groups of proteins.
When bringing the thiolated polymers into contact with the mucosa, their pronounced
mucoadhesiveness can be explained by disulfide bond formation between the sulfhydryl
groups of the polymer and cysteine-rich subdomains of glycoproteins in the mucus
layer [83]. Thus, a correlation between the amount of conjugated thiol groups in the
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polymer and the mucoadhesive bond strength has been revealed [84]. Furthermore, and as
demonstrated for thiomers from poly(acrylic acid) (PAA), the extent of immobilization of
thiol moieties is augmented when thiolation is conducted in organic solvents, as is their
mucoadhesive character [85]. Nonetheless, thiol content is not the only parameter involved
in mucoadhesive capacity. Rapid formation of disulfide bridges with thiol groups on the
surface of the mucosal tissue is not advisable because the thiomer-based drug carrier will be
eliminated faster by the mucus turnover process [13]. Additionally, adhesion improves with
flexible polymer chains so the entanglement between the underlying mucus substructures
within the polymer matrix is facilitated [10]. In this case, both the entanglement and the
mucosal network structure will take place with the formation of disulfide bonds by means
of the reaction of the thiomers with the cysteine subdomains within the mucosal layer. This
reinforcement is prevented when thiomers with poorly reactive mercapto groups are used.
Therefore, thiol moieties must have the appropriate reactivities, the most favorable pKa
values being those near 8, as it is also preferred by nature in the form of Cys. Lastly and
not surprisingly, a sufficient hydration of the thiolated polymer is a prerequisite for the
mobilization of polymer chains. Thus, the use of hydrophilic thiomers that bear functional
groups capable of forming hydrogen bonds greatly improved this property [86]. It is worth
mentioning that preactivated thiomers have demonstrated an ability to exert improved
mucoadhesion in several polymers and applications [87–89].
Another of the exceptional characteristics attributed to thiomers is their behavior as a
permeation enhancer through the opening of tight junctions (TJs) of epithelial cells caused
by the interaction of thiomers with cysteine-bearing membrane receptors and enzymes [90].
When used in oral DDSs, they can adhere to the mucosa of the intestine [91], thereby
inhibiting the enzymatic degradation of APIs and enhancing drug permeation via opening
TJs of epithelial cells. Zhang et al. [92] proposed that, by interacting with a highly expressed
cysteine-rich membrane receptor like epidermal growth factor receptor (EGFR), thiomers
activate Src phosphorylation and further disrupt claudin-4, which results in the TJs opening
eventually. The effect was found to be reversible, and the integrity of the epithelium was
restored when the contact with the polymer was discontinued [93]. In permeation studies
of model compounds, thiomers display comparatively more prolonged effect and lower
toxicity than low-molecular-weight permeation enhancers [94]. The effect could be further
improved by the addition of the permeation mediator GSH [94,95]. However, this property
can drop substantially for thiomers with free sulfhydryl groups in a normal intestinal
environment since, as mentioned above, thiol groups are prone to be oxidized under such
conditions. Preactivated thiomers, with the protective 2-pyridylthio-based moiety, impede
the premature oxidation of sulfhydryl groups so their functionality is preserved. They
have demonstrated great merits in oral delivery of protein/peptide drugs by triggering the
opening of tight junctions of epithelial cells [96].
A thiomer-based DDS can be the option of choice when dealing with the issue known
as multidrug resistance (MDR) in anticancer therapy. MDR is a phenomenon whereby cells
confer resistance to structurally and functionally unrelated APIs, such as chemotherapeutic
drugs, antibiotics, cardiac glycosides, and antiretroviral APIs. Multidrug-resistant proteins
like P-glycoprotein and MRP1 are responsible for the reduced bioavailability of such drugs
in numerous cases of cancer. The role of in drug resistance was first reported by Juliano
and Ling [97]. Elevated P-gp expression has been documented in various drug-resistant
tumors, thereby enabling direct drug efflux, and limiting intracellular accumulation of
anticancer agents that serve as substrates for this transporter [34]. Thiomers can form
disulfide bonds with the cysteine subunits present in P-gp and MRP1 transmembrane-
channel-forming structures, and thereby inhibit the activity of these transporters (inhibition
of efflux pumps) [12,98].
Additionally, API-loaded thiolated carriers experience enhanced absorptive endocyto-
sis by disulfide formation with exofacial thiols of transmembrane proteins [31,99,100].
The use of thiolated materials as a constituent of NPs can make the nanocarrier reactive
under the environments found in cancer tissues; hence, thiomer-based nanocarriers behave
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as smart DDSs, not only for conventional chemotherapeutics, but also for other novel APIs
like small interfering RNA (siRNA), as will be discussed below. However, to keep the
nanocarrier stable in the blood circulation before it reaches the target, stable and strong
interactions are needed. Disulfide bonds are amply stable in the blood circulation, but they
are prone to rapid cleavage under a reductive environment through the fast and readily
reversible thiol–disulfide exchange reactions [13]. Thus, thiomer-based, drug-loaded NPs
crosslinked by disulfide linkages could maintain their integrity in the bloodstream and
were later disintegrated in tumor surroundings by means of GSH [36,101].
It is evident that thiomers have demonstrated promising properties that can make
them a useful tool in the development of novel formulations for clinical use. Pathologies
that are nowadays treated with rather toxic compounds (or those that do not even have an
effective treatment) can find new horizons to tackle in these materials. Without a doubt,
anticancer therapy is one of the main fields in which thiolated polymers are breaking
through more evidently, which certainly will continue in the near future.
4. Thiolation of (Semi)Natural-Occurring Polysaccharides
Although thiol chemistry is already well developed, the emergence of these new mate-
rials has prompted research in this field, with the design of a wide variety of materials that
have been prepared using a plethora of synthetic procedures, many of them centered on the
derivatization of (semi)natural-occurring polymers such as chitosan and hyaluronic acid.
4.1. Strategies for the Thiolation of Multiamino Polymers
The most common way to prepare thiolated polymers is by derivatization of
(semi)natural polymers such as chitosan, hyaluronic acid, cellulose, dextran, cyclodextrins,
etc., the former being the polysaccharide on which more research has been conducted.
The accumulated information about the physicochemical and biological properties
of chitosan (CTS) led to the recognition of this polymer as one of the most promising
material for DDSs [35]. The polysaccharide CTS, a weak cationic polysaccharide com-
posed of randomly distributed β-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine
repeating units, is a copolymer prepared from renewable resources. It can be obtained
from the partial deacetylation of the second most important natural polymer in the world:
chitin or poly(N-acetyl-β-D-glucosamine). Its abundance in marine crustaceans, such as
shrimp and crabs, makes it a commercial product with global impact in polymer science.
CTS bears exceptional properties such as nontoxicity, biocompatibility in vitro and in vivo,
degradability, and a broad activity spectrum against Gram-positive/negative bacteria and
fungi [18]. On the other hand, CTS can interact with negatively charged polymers, macro-
molecules, and even with certain polyanions upon contact in an aqueous environment.
These interactive forces and the resulting sol–gel transition stages have been exploited for
nanoencapsulation purposes [102]. Moreover, CTS has the special feature of adhering to
the mucosal surfaces within the body, a property leading to the attention to this polymer
in mucosal drug delivery [103]. The potential of CTS for this specific application has
been further enforced by the demonstrated capacity of chitosan to open tight junctions
between epithelial cells though well-organized epithelia [104]. Consequently, due to the
interesting biopharmaceutical characteristics of this polymer, accompanied by its well doc-
umented biocompatibility and low toxicity, numerous articles on the potential of chitosan
for pharmaceutical applications have already been published [105–108].
From the synthetic point of view, the presence of the nucleophilic amino group in
the CTS structure is capable of imparting distinctive reactivity to the material, which
differentiates it from other polymers, making it a unique polysaccharide. Thus, the amino
groups of chitosan are responsible for most of its derivatization reactions on the way to
thiolated polymer formation; Figure 8 displays the most common synthetic techniques
used. CTS, poly(lysine), and polyethyleneimine (PEI) are examples of cationic multiamino
polymers, and although the chemistry described next has been developed using as starting
material CTS or its derivatives, it could be extended to other multiamino polymers.
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Figure 8. Reported routes to thiolated multiamino polymers.
4.1.1. Coupling Reaction of Multiamino Polymers and Mercaptocarboxylic Acids
Thiol-bearing compounds can be covalently linked to multiamino polymers via the
formation of amide or amidine bonds, the former being the preferred strategy. There are
several approaches developed with such targets that will be described next.
The most common reaction to include sulfhydryl groups into multiamino polymers
is the coupling reaction between the amino groups and the carboxylic acid groups from
mercaptocarboxylic acids mediated by a water-soluble carbodiimide: the 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDAC, Reaction 1 in Figure 8). This is by far the most
common method used to form thiolated CTS, as summarized in Table 1, which records
some examples of mercaptocarboxylic acids used, with L-cysteine (Cys), the tripeptide
glutathione (GSH), and thioglycolic acid (TGA) being especially relevant. The final degree
of functionalization (thiol group concentrations) on the thiomers are usually determined
via Ellman’s reagent (5,5′-dithiobis-(2-nitrobenzoic acid), DTNB) according to literature
protocols [109].
Some CTS derivatives with an enhanced hydrophilic character are often chosen,
such as glycol CTS [26,110] and CTS-graft-PEG-SH, the latter being soluble in aqueous
solutions with pHs above 8 [111]. These materials might show potential as auxiliary
agents in oral drug delivery, where their solubility is likely beneficial. Similarly, the
use of Cys as thiolating agent provides the material with an additional advantage: the
presence of carboxylic groups increases the water-solubility of CTS at neutral and basic
pHs. This characteristic is highly desirable, bearing in mind that the limited solubility of
chitosan (i.e., at pH > 6.0) may compromise its application in various biomedical fields [62].
The N-acylation of CTS with fatty acids with diverse alkyl chain lengths and degrees of
substitution modify the hydrophilic-hydrophobic balance of the material, and hence its
properties for future applications. Thus, selected N-alkyl derivatives of CTS, although
exhibiting reasonable water-solubility, can display self-assembly properties that lead to
micellar aggregation, with potential applications as DDSs, nucleic acid transfection in
gene therapy, and blood compatibility [112]. Thiolated CTS derivatives can self-assemble
into core-shell structured NPs when CTS is thiolated using lipophilic ligands such as
4-mercaptobenzoic acid (4-MBA) [70]. On the other hand, a reduction in the degradation
behavior of CTS-based thiomers is observed both when increasing the hydrophobicity of
the thiol precursor, and when it is crosslinked through the formation of disulfide bonds, a
useful feature in applications such as core-crosslinked NPs [25] and 3D bioscaffolds [62].
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Table 1. Mercaptocarboxylic acids (HS-R-COOH) used for the preparation of CTS-based thiomers by means of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDAC)-mediated coupling






Formula Abbrev. Formula Abbrev.
1a
n = 1, 2, 3, 5, 7, 10
n = 1: Thioglycolic acid
n = 1: TGA
n = 2: MPA
n = 3: MBA
n = 5: MHA
n = 7: MOA
n = 10: MUA
n = 1: [18,23,29,70]
n = 2: [18,113]
n = 3: [18]
n = 5: [18]
n = 7: [18]































Note: MBA: 4-mercaptobutanoic acid; MHA: 6-mercaptohexanoic acid; MOA: 8-mercaptooctanoic acid; MPA: 3-mercaptopropanoic acid; MUA: 11-mercaptoundecanoic acid.
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The thiolation process can be improved by the combined use of N-hydroxysulfos-
uccinimide [20,110] or N-hydroxysulfosuccinimide sodium salt (Sulfo-NHS) with EDAC as
a zero-length coupling agent (stabilization of intermediates formed) [19,62]. For example,
being the single-EDAC thiolation procedure satisfactory for the coupling of ligands such
as NAC and TGA, the GSH coupling reaction significantly improved the thiol yields when
EDAC and NHS were added [70].
When using thiolating agents with unprotected free sulfhydryl groups such as the
mercaptocarboxylic acids recorded in Table 1, disulfide linkages can be formed with the
correlated decrease in free sulfhydryl group concentration in the polymer. If necessary, and
in order to avoid it, a reducing agent can be added near the end of the coupling reaction,
with tris(2-carboxyethyl)phosphine hydrochloride (TCEP) being one of the most widely
used. For example, Croce et al. have applied this methodology to the development of a
number of N-acyl thiomers as potential antibacterial materials [18]. Mueller et al. found
that aromatic ligands such as 4-MBA and 6-mercaptonicotinic acid (6-MNA) required TCEP
as a reducing agent in a final concentration of 10 mM [70]. The reduction process can take
place after the coupling reaction and other reducing agents, such as DTT, can be used [20].
This is the reason why free sulfhydryl groups from freshly synthesized thiomers are
frequently protected or/and preactivated to preserve the materials’ properties (Reaction
1b—preactivation—in Figure 8; Scheme 1). Among the protecting and preactivating groups,
the (pyridin-2-yl)thio-based moiety not only has the ability to protect the mercapto group
from oxidation reactions, but also preactivates it for reaction with Cys residues in the
human body. In general, free unprotected thiol groups from thiomers can react with
disulfide bonds of proteins, whereas S-protected/preactivated thiol groups from thiolated
materials may react with free thiol groups from Cys residues in proteins [13]; also noticeable
is the discovery that thiolated chitosan derivatives with thiols protected by a good leaving
group are more mucoadhesive than their S-unprotected counterparts [116,117].
Scheme 1. Example of preactivation reaction of thiomers containing free sulfhydryl groups with disulfides derived from
nicotinic acid by thiol–disulfide exchange reaction (Reaction 1b in Figure 8). 2,2′-DTNA: 2,2′-dithiodinicotinic acid; 2-MNA:
2-mercaptonicotinic acid.
The protection and preactivation of sulfhydryl moieties in thiomers can take place
by means of a thiol–disulfide exchange reaction. The disulfide molecules most frequently
employed for this purpose are 2,2′- and 6,6′-dithiodinicotinic acid (2,2′-DTNA and 6,6′-
DTNA, respectively) and 6,6′-dithiodinicotinic amide (6,6′-DTNAm), as recorded in Table 2.
In addition, the dimer of 3-methyl-1-phenylpyrazole-5-thiol (MPPT) has been chosen with
the same objective. The electron-withdrawing effect exerted by the π-deficient pyridine
rings makes the synthesized asymmetric disulfide linkages more reactive to thiol–disulfide
exchange reactions and more easily cleaved off, and hence, its preactivation is ensured [13].
This methodology was used, for example, to S-protect/preactivate quaternary ammo-
nium CTS thiomers (QA-CTS-TGA-SH). The S-protected and preactivated polymer QA-
CTS-TGA-S-6-MNAm was obtained by disulfide bond formation with 6-MNAm through
reaction with 6,6′-DTNAm [116].
Nicotinic acid derivatives such as 2-MNA and 6-MNAm are preferred as leaving
groups to 2-mercaptopyridine in these types of reactions due to safety reasons [118].
Therefore, the most used reagents to protect free thiol groups are 2,2′-DTDNA, 6,6′-DTNA,
and 6,6′-DTNAm. Interestingly, the antimicrobial properties of MPPT were considered
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in the preactivation of CTS-TGA-SH with the dimer of MPPT by Müller et al. [83]. The
preactivated CTS-S-S-MPPT released the antimicrobial MPPT into the medium, so this
thiomer might be used for the treatment of infected tissues.
Quantification of the total free sulfhydryl groups remaining after the preactivation
step indicated that although the reaction worked reasonably well, full protection of the
sulphydryl groups was not achieved. For example, values close to 80% were found by
Netsomboon et al. for EDTA functionalized CTS-Cys-2-MNA [48].
Table 2. Disulfides used for the preactivation via a thiol–disulfide exchange reaction of already-prepared thiomers (Reaction


















This drawback is overcome when protected mercaptocarboxylic acids (Table 3) syn-
thesized “ex profeso” are used. They react (EDAC-mediated) with the amino groups from
the polymer (Reaction 2 in Figure 8), so the global of the incorporated thiol groups is
preactivated. Among the sulfur-containing reagents, 2,2′-DTDNA and NAC-6-MNAm
stand out. The S-preactivated NAC-6-MNAm can be prepared via a thiol–disulphide
exchange reaction between NAC and 6,6′-DTNAm [120].
Table 3. Disulfides used for the formation of preactivated chitosan-based thiomers by 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDAC)-mediated coupling reactions (Reaction 2 in Figure 8) between the













4.1.2. Reaction of Multiamino Polymers with Highly Reactive Carboxylic Acid Derivatives
Reaction with N-hydroxysuccinimide Esters
The use of activated carboxylic acid derivatives, such as reactive N-succinimidyl
carboxylates, is necessary for the formation of an amide bond between the multiamino
polymer and the reagent bearing the mercapto group without the concourse of a coupling
reagent such as EDAC (Reaction 3 in Figure 8). These active esters usually carry the
sulfhydryl groups conveniently masked to avoid interferences during either the coupling
or the work-up reactions. They are usually protected as acetylthio- or 2-pyridyldithio
groups (Table 4). The former can be cleaved by a basic medium such as sodium hydroxide,
potassium carbonate, or sodium methoxide, or by treatment with hydroxylamine to render
the free thiols [13,60,95,121]; in the case of 2-pyridyldithio groups, they will be deprotected
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either using a reductive reagent such as NaBH4 [93] or TCEP [55], or by a thiol–disulfide
exchange reaction when treated with DTT, Cys, or GSH [12,122].
Table 4. (Protected) thiol-containing active esters (N-hydroxysuccinimide esters) for thiolation of multiamino polymers and
chemical structure of the reactive acetimidate isopropyl (acetylthio)acetimidate (i-PATAI). Reagents used for Reactions 3































An interesting example that utilizes this methodology is the thiolation of glycol CTS poly-
mers by treatment with sulfosuccinimidyl-6-(3′-[2-pyridyldithio]-propionamido)hexanoate
(sulfo-LC-SPDP) and subsequent reduction with DTT [122,124]. The resultant thiomer was
able to form stable NPs with anionic polymerized siRNA (poly-siRNA) through charge–
charge interactions, resulting in loosely bound large structures. Consequently, the distance
between the thiol groups decreased, which allowed undergoing intra- and intermolecular
crosslinking by formation of disulfide bonds, leading to more condensed nanostructures.
The formation of the N-hydroxysuccinimide ester can also be achieved in situ by
adding N-hydroxysuccinimide (NHS), as was the case with GSH [60]. Another alternative
is the activation of the thiocarboxylic acid as N-hydroxybenzotriazole (HOBt) esters prior
to its reaction with the multiamino polymer. Moreover, Liu et al. described the synthesis of
preactivated NAC (Table 4) in organic solvents prior to its reaction with CTS at pH 5 [125].
This succinate ester methodology has also been applied to the functionalization of APIs
such as the monoclonal antibody cetuximab (CTX). CTX was derivatized by reaction with
N-succinimidyl-S-(acetyl) thioglycolate (SATA; Table 4), so that CTX would be anchored to
poly(lactic-co-glycolic) acid (PLGA)-CTS NPs by means of a Michael reaction with the PEG
extender [80]. Similarly, a methacrylamide-modified lysozyme containing a bioreducible
linker was prepared by reaction with SATA. The antimicrobial enzyme was temporary
immobilized in a dextran-based network, and then its release was triggered by GSH [123].
Reaction with Acetimidates
Imidoesters (or imidates) (R-O-C(=NH)-R’) react with nucleophiles such as amines to
form amidines (Reaction 4 in Figure 8). The amidine functional group is among the most
basic, noncharged ones. In general, they are more basic than amines. Their pKa ranges
between 5 and 12, so that they could be protonated at physiological pH (imidinium ions),
making a polymer with low solubility, such as CTS, soluble at physiological pH [95].
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The imidoester reaction scheme for the chemical modification of chitosan was used for
the first time by Kafedjiiski et al. in 2005 [121]. They used isopropyl (acetylthio)acetimidate
(i-PATAI) as the thiol-bearing chemical with its sulfhydryl group deprotected as the S-
acetyl group (Table 4), and it was observed that the deprotection of S-acetyl groups could
partially and spontaneously occur at pH≈ 7.0 [121]. To achieve a quantitative deprotection,
treatment with NaOH or NH2OH should be conducted, the latter being a method used at
near neutral pH. In general terms, imidoesters react rapidly with amines (1.5 h) under the
optimal conditions (30 ◦C and pH 7–10), in contrast with the reaction with 2-iminothiolane,
which ends after 24 h and shows unintended cyclization side reactions [126]. Since CTS is
not soluble at such pH, the reactions are conducted at pH 6.5–7.0 [121]. However, disulfide
bond formation occurs. When CTS reacted with i-PATAI, and then deprotected with
NH2OH, the 48% of immobilized thiol groups were participating on disulfide linkages [95].
The formation of disulfide linkage is directly correlated with thiolate concentration, so
the higher the pH is, the greater the ratio of sulfhydryl groups involved in disulfide bond
formation becomes. For example, films of CTS–NAC conjugates were crosslinked at basic
pH (pH 11) with a substantial improvement in their mechanical properties, and with almost
no mercapto groups present in the materials [64]. This is the reason why an additional
treatment with a reducing agent is advisable in this methodology, with TCEP being a
common choice [95].
4.1.3. Thiolation in Two Steps: Nucleophilic Reactions of Multiamino Polymers with
Chloro-Derivatives and Incorporation of Thiol Moiety
Other synthetic options include the use of bis-electrophiles that can act as anchoring
moieties between the multiamino polymer and a thiol-bearing nucleophile. Chloroacetyl
chloride and epichlorohydrin are the two bis-electrophiles most widely used in the deriva-
tization of CTS.
Reaction with Chloroacetyl Chloride
Acyl chlorides are among the most reactive carboxylate derivatives, and they can
react readily with amino groups. Chloroacetyl chloride is a double electrophile that can
ensure the connection with two nucleophiles, such as the amino groups from the polymer
and a nucleophile from the thiol carrier. The reaction of CTS with chloroacetyl chloride in
the presence of pyridine leads to the formation of an amide bond (Reaction 5 in Figure 8).
The as-synthesized chlorinated chitosan was further transformed in the thiol structure
via thiourea [51]. The thiouronium salt intermediate is usually cleaved by treatment with
sodium hydroxide [49,51,116]. Due to the high reactivity of acyl chlorides, the reactions
are not usually restricted to amino groups. In polysaccharides and under the reaction
conditions, a certain degree of their hydroxyl groups may react with chloroacetyl chloride,
and hence the degree of thiolation per monosaccharide unit can be higher than one in the
final polymer.
Reaction with Epichlorohydrin
Similar to what was found with chloroacetyl chloride, this doubly electrophilic reagent
can react with both amino groups and hydroxyl moieties activated in basic media. This fea-
ture is related to some crosslinking phenomena found by this methodology, and therefore,
this approach is frequently chosen when looking for the preparation of resins, beads, or
microspheres, especially for the adsorption of heavy-metal cations such as Au(III), Pd(II),
Pt(II), Hg(II), Cu(II), and Ni(II) [50,52,127]. Once the oxirane ring is opened by the nucle-
ophilic attack of the amino or alkoxide groups, the incorporation of the thiol moiety can take
place via treatment with thiourea [49,52] or via reaction with selected thio-functionalized
triazoles [127] or thiazoles [50] (Table 5) rendering the thiolated material (Reaction 6 in
Figure 8). Contrary to the cases studied above, the joining bond between the multiamino
polymer and the thiol-bearing residue is a basic secondary amino group that, from the
toxicological point of view, might be disadvantageous for their use in humans [13].
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Table 5. Nucleophilic thiolating agents used for nucleophilic substitution reactions of multiamino polymers (Reactions 5


















One example of this methodology is the preparation of magnetic CTS microspheres as
a chelating agent. Magnetic CTS microspheres, previously crosslinked with glutaraldehyde,
were the starting material for the grafting of sulfur groups using epichlorohydrin as a
second crosslinking agent. The magnetic CTS microspheres were chemically modified with
thiourea for adsorption of metal ions (Hg2+,Cu2+, and Ni2+) [52].
4.1.4. Ring Opening of Reactive Thiolating Cycles: 2-Iminothiolane and Thiolactones
One of the most reactive thiolating cycles is the 2-iminothiolane (Traut’s reagent;
Table 6), a well-known reagent frequently used in the immobilization of thiol groups to
primary amino groups of proteins [69]. This cycle reacts with primary amines to introduce
sulfhydryl groups while maintaining charge properties like the original amino group.
The reaction of 2-iminothiolane with CTS renders CTS-(4-thiobutylamidine) conjugates
(Reaction 7 in Figure 8). This coupling reaction has been tested at acidic (pH 5.0, 6.0),
neutral (pH 7.0) and basic (pH 10.0) conditions [30,69,70,128]. Due to the lower reactivity of
2-iminothiolane in acidic media [128], the degrees of thiol substitution found at neutral pH
were substantially higher than those achieved under equivalent conditions, but at acidic
pH [30,69]. The use of basic pH did not render the expected enhanced degree of thiol
substitution, probably due to the reduced solubility of CTS in such media [69]. On the other
hand, and as mentioned before, the higher the pH of the medium, the greater the tendency
of disulfide bond formation from free thiol groups; therefore, a compromise solution
should be reached regarding the pH of the reaction media. Additionally, the reaction
of CTS with 2-iminothiolane is usually conducted under an inert atmosphere to prevent
oxygen-mediated thiol oxidation [25,67], and the addition of sulfhydryl-based reagents
such as DTT and 2-mercaptoethanol has also been reported with the aim of keeping the
thiol groups as such [30,69].
Another type of reactive cycles used as thiolating agents are the thiolactones (Reaction
8 in Figure 8), with the most widely used being those derived from γ-thiobutyrolactone,
with or without a substituent on the γ-position of the cycle (Table 6). As in any nucleophilic
reaction in which amino groups are involved, the pH of the media is crucial to optimize the
degree of thiol substitution. These reactions are conducted at pH 6–7 in every case using
different buffer systems, such as the 2-(N-morpholino)ethanesulfonic acid (MES) [67,129],
classified as a “Good’s buffer”, or imidazole buffer [130]. The reaction of multiamino
polymers with such cyclic thiolating agents leads to polymer-(4-thiobutylamide) conjugates
in good yields without the concomitant release of small molecules found in other methods.
To sum up, a plethora of synthetic methods is available for the thiolation of CTS,
the most popular being the coupling reaction with mercaptocarboxylic acids (protected/
preactivated or not) and the reaction with reactive carboxylic acid derivatives such as
N-hydroxysuccinimide esters. These procedures can be implemented to achieve the deriva-
tization of other multiamino polymers, with the consequent enlargement of potentially
available thiolated materials with tailor-made properties.
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Table 6. Thiolactones and 2-iminothiolane used as thiolating agents in reactions with multiamino polymers (Reactions 7



















4.2. Strategies for the Thiolation of Multicarboxyl Polymers
Another interesting polymer for biomedical and pharmaceutical applications in tis-
sue engineering, regenerative medicine, and as a drug delivery system, is the anionic
biopolymer hyaluronic acid [68]. HA is a nontoxic, biocompatible, greatly biodegradable,
and nonimmunogenic polysaccharide that is present in connective tissue as a major com-
ponent of the extracellular matrix, and can be metabolized via enzymatic hydrolysis by
hyaluronidase (HAase). It is a material that can also induce cell proliferation, wound
healing, and angiogenesis [78,131,132]. Perhaps the most remarkable advantage of HA is
its potential for active targeting without any additional targeting ligands. HA has a strong
affinity for cell-specific surface markers such as CD44 and RHAMM, and as a result, has
drawn much attention from the scientific community [132].
HA is constituted by alternating disaccharide units of D-glucuronic acid and N-acetyl-
D-glucosamine, linked via alternating β-(1→4) and β-(1→3) glycosidic bonds. Due to the
presence of carboxylic groups (-COOH) and hydroxyl groups (-OH), HA can be chemically
modified by robust synthetic strategies, and such is the case for the thiolation methods. The
attachment of free thiol groups on the polymeric backbone provides the new materials with
enhanced mucoadhesive features, as well as in situ gelling properties [17,133]. Although
some commercial HA-derived thiols are available and have been utilized in various research
works [134,135], there are reliable thiolating approaches than can be applied to a number
of multicarboxyl polymers: from the natural HA [14] and pectin (Pec) [29] to the synthetic
PAA and poly(methacrylic acid) (PMAA), and their copolymers [85].
The thiolating methods designed for multicarboxyl polymers are mainly based on
EDAC-mediated coupling reactions (Reactions 1–6 in Figure 9), already described in the
previous section. The thiolating reagents can be aminothiols or their dimers (Reactions 1
and 2 in Figure 9), such as cysteamine (CSA), Cys and cystamine (Table 7), preactivated
aminothiols (Reaction 5 in Figure 9), and symmetric or asymmetric dithiobis(dihydrazide)s
(Reactions 3 and 4 in Figure 9).
The coupling reaction between an anionic polymer and a free, dimerized, or preacti-
vated aminothiol (Reactions 1, 2, and 5, respectively, in Figure 9) is usually conducted in
aqueous media, with EDAC being the carbodiimide of choice. To potentiate the reactivity
of the carboxylic acid groups of the anionic polymer before coupling occurs, the addition
of NHS [15,16,71,78] or HOBt [31,136] is quite common. On the other hand, Baus et al.
studied the impact of the absence of water during the synthesis of thiolated PAA both from
Cys and Cys-2-MNA [85]. They found that the extent of functionalization under aqueous
conditions was lower than with organic solvents. The approach of a water-free thiomer
synthesis improved immobilization of thiol groups up to 4.2-fold in comparison to function-
alization in aqueous media, probably due to the greater stability of the coupling reagents
used (N,N′-diisopropylcarbodiimide (DIC) and 1,1′-carbonyldiimidazole (CDI) for Cys
and Cys-2-MNA, respectively) and the active intermediates involved. When cystamine, the
dimer of cysteamine (CSA) is used as a thiolating agent, the obtained crosslinked materials
have to be reduced, usually with the concourse of DTT [15,31,136].
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Figure 9. Reported routes to thiolate multicarboxyl polymers.
Other very popular thiolating reagents when functionalizing HA are dithio(bis)
hydrazides such as N-acetyl-S-((3-hydrazineyl-3-oxopropyl)thio)-cysteine (NAC-TPH) [17],
3,3′-dithiobis(propanoic hydrazide) (DTPH) [14,63,79,137], and its derivatives (Table 7;
Reactions 3 and 4 in Figure 9) [63]. Similar to what occurs in the synthetic pathway with
dimers of aminothiols, the presence of disulfide linkage in the hydrazide may necessitate a
reduction step after the coupling reaction [14,63,79,137].
Table 7. Methodology (related to Figure 9), anionic polymer, thiolating agents, and coupling reagents used for the
preparation of thiomers derived from multicarboxyl polymers.
Reaction Code Polymer
Compound Coupling Reagents Used
and Other Reaction Details Ref.Formula Abbrev.
1 HA
Cysteamine



















1.- EDAC + HOBt
2.- DTT [31,136]
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Table 7. Cont.
Reaction Code Polymer
Compound Coupling Reagents Used
and Other Reaction Details Ref.Formula Abbrev.
3 HA
3,3’-Dithiobis(propanoic hydrazide)
DTPH 1. EDAC2. TCEP [14,79]
3 HA











NAC-TPH EDAC + NHS [17]
5 PAA
Cysteine 2-mercaptonicotinic acid adduct
Cys-2-MNA
EDAC + NHS (in H2O)
or
CDI (in DMF-DCM mixtures)
[85]
5 Pec
Cysteine 2-mercaptonicotinic acid adduct









Note: HA: hyaluronic acid; CDI: 1,1’-carbonyldiimidazole; DCM: dichloromethane; DIC: 1,3-diisopropylcarbodiimide; DMAP: 4-
(dimethylamino)pyridine; DMF: N,N-dimethylformamide; DTT: dithiothreitol; EDAC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide;
HOBt: N-hydroxybenzotriazole; NHS: N-hydroxysuccinimide; PAA: poly(acrylic acid); Pec: pectin; TCEP: tris(2-carboxyethyl)phosphine;
XrL: crosslinked.
Other approaches rely on the initial coupling reaction between the carboxylic acid
groups from anionic macromolecules and one of the amino groups from diamines to render
multiamino polymers (Reaction 6 in Figure 9). These materials can then be thiolated by any
of the methods listed in Figure 8. This is the case of the preparation of injectable HA hydro-
gels crosslinked with the macro-crosslinker PEG-dithiol reported by Choh et al. [138]. HA
was coupled with diaminohexane using carbodiimide chemistry to yield amino-derivatized
HA (HA-CO-(CH2)6-NH2), followed by a reaction with SPDP, generating HA derived with
pyridyl disulfide, ready for the crosslinking process (Scheme 2).
In summary, interesting and reliable methods are available for preparing HA-based
thiomers with smart properties for their applications in cancer therapy.
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Scheme 2. Transformation of HA to preactivated thiol-bearing HA (Reaction 6 from Figure 9) for its later crosslinking with
the macro-crosslinker PEG-dithiol [138].
4.3. Nanostructures from Chitosan and Hyaluronic Acid-Based Thiomers
In the design of NPs as DDSs, particle size is an essential parameter for cellular uptake.
For example, the permeability of the NPs through the intestinal mucosa decreases when
the particle size reaches 400–500 nm [139]. On the other hand, NP-based delivery systems
with size ranges of 100–500 nm are known to efficiently accumulate at tumor sites through
fenestrate vasculature (EPR effect) [140]. Therefore, when preparing nanostructured DDSs
from polysaccharides such as CTS or HA, the molecular weight of the material exerts a
significant effect on formulation size and drug delivery. This outcome was demonstrated
for CTS glutamate and CTS aspartate NPs produced by ionotropic gelation with sodium
tripolyphosphate (TPP), using bovine serum albumin as a model protein. In those experi-
ments, CTS from low-molecular-weight (35 kDa) to medium- and high-Mw CTS (100 and
800 kDa) were used, and the particle sizes varied from 195 to 3450 nm. Nanoparticles
prepared with the highest molecular weight CTS showed the largest sizes [141]. This is the
reason why low-weight CTS is usually chosen in the design of nanoparticulated DDSs; for
example, NPs prepared for nose to brain codelivery of alpha-cyano-4-hydroxycinnamic
acid and the monoclonal antibody cetuximab were obtained by ionic interaction between
oligomeric CTS and poly(lactic-co-glycolic) acid (PLGA) [80].
This effect was also studied in docetaxel-loaded NP prepared from amphiphilic CTS–
GSH–graft–PMMA (poly(methyl methacylate)) thiomers. The starting CTS polymers had
molecular weights of 20, 50, and 100 kDa (Table 8) [27]. The NPs were drawn up by radical
emulsion polymerization of MMA on thiolated CTS–GSH, using cerium IV ammonium
nitrate (CAN) as a radical initiator. The amphiphilic block-copolymers were capable of
self-assembling in aqueous media. The mean sizes of the NPs (ranging from 153 to 264
nm) were highly and positively dependent on the molecular weights of thiolated CTS
used. Thus, the thiolated CTS with the lowest molecular weight (20 kDa) and the highest
free thiol content on their surface were used for the optimal formulation of DTX-loaded
NPs [27]. Self-assembly of CTS-based thiomers with hydrophobic subdomains was also
observed for the amphiphilic carboxymethyl-CTS derivatized with 4-mercaptobenzoic acid
(4-MBA) via EDAC procedure. These NPs were core crosslinked by air oxidation under
ultrasonication. Adjacent thiol groups in the hydrophobic core produced disulfide bonds,
leading to pH- and redox-responsive NPs with average diameter of 160 nm [25].
One of the most widely used methods for NP formation from ionic polysaccharides
such as HA and CTS-based thiomers is ionic gelation (ionic crosslinking) mediated by
a counter ion. Thus, CTS-based NPs were formulated via gelation with sodium sulfate
as nanocarriers for doxorubicin (DOX) and antisense oligonucleotide (ASOND). They
displayed a spherical, uniform shape with a mean particle size of 150–300 nm [114]. Another
option for CTS-based particles is ionic gelation with TPP, feasible for both CTS and thiolated
CTS–GSH [29]. For anionic thiomers such as HA or PAA, cations like Ca2+ can be used
to stabilize the NPs. Dünnhaupt et al. achieved the successfully load of the hydrophilic
macromolecule fluorescein isothiocyanate–dextran (FD4) in NPs of PAA–Cys stabilized
with Ca2+ for its oral delivery [29]. They also found that the addition of trehalose in a
concentration of 3% to NP suspensions avoided particle aggregation.
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Table 8. NPs formation from hyaluronic acid and chitosan-based thiomers.
System Particle Formation Method Crosslinker(s) APIs Thiomer NP Size (nm)/PdI Ref.
Microparticles Spray-drying technique — FDA CTS–NACCTS–GSH 800–2270/— [110]
NP Self-assembly of the amphiphilic material — Docetaxel CTS–GSH–graft–PMMA <200/<0.15 [27]
NP Self-assembly of the amphiphilic material Air core XrL(ultrasonication) Methotrexate CM–CTS–Ph–SH
a 160/0.055 [25]





NP Ionic gelation TPPCa2+ FD4
CTS–TGA with TPP
PAA–Cys with Ca2+ 220–280/— [29]
NLC Polyelectrolyte complex formation Negatively chargedCUR-loaded NLC Curcumin CTS–NAC 89/— [125]






Double polyelectrolyte complex formation:
1. pIL-12 + DOX-Loaded
polymetformin micelles
2. Micelleplexes + HA-SH




DOX and pIL-12 HA–SH 98–192/— [136]
Hybrid nanoplex Polyelectrolyte complex formation andionic gelation
Negatively charged insulin
TPP Insulin Thiomalyl–CTS 365/— [24]
Nanosuspension Polyelectrolyte complex formation andionic gelation
HA
TPP Isoniazid CTS–TGA 300–500/— [23]
NP Polyelectrolyte complex method anddisulfide bond formation
bFGF
Thiol oxidation (air, pH 7.4) bFGF
Carboxymethyl(sulfate)–
CTS–thiobutylamidine 218–290/— [30]
NP Polyelectrolyte complex method anddisulfide bond formation
Poly-siRNA
Thiol oxidation (air, pH 8.0,
37 ◦C)




and disulfide bond formation
Poly-siRNA
Calcium phosphate siRNA HA–SH 169/0.108 [31]
a Thiolating agent: 4-mercaptobenzoic acid. 6-MNAm: 6-Mercaptonicotinamide; ASOND: antisense oligonucleotide; bFGF: basic fibroblast growth factors; CM: carboxymethyl; CTS: chitosan; CUR: curcumin;
Cys: cysteine; DOX: doxorubicin; FD4: fluorescein isothiocyanate–dextran; FDA: fluorescein diacetate; GSH: glutathione; HA: hyaluronic acid; HPMAm: hydroxypropylmethacrylamide mono- or dilactate; Mw:
molecular weight; NAC: N-acetylcysteine; NAP: N-acetylpenicillamine; NLC: nanostructured lipid carrier; PAA: poly(acrylic acid); pIL-12: plasmid-encoding IL-12 gene; PdI: polydispersity index: PMMA:
poly(methyl methacrylate); QA: quaternary ammonium; siRNA: small interfering RNA; TGA: thioglycolic acid; TPP: tripolyphosphate; XrL: crosslinked.
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A general approach to produce NPs is by polyelectrolyte complex formation between
two ionized polymeric materials with opposite charges in their structures. For example,
NPs based on thiomers from quaternary ammonium (QA) CTS (both QA-CTS-TGA-SH
and the preactivated thiomer QA-CTS-TGA-S-S-6-MNAm) were prepared by self-assembly
upon addition of reduced-molecular-weight hyaluronic acid (rHA: 470 kDa), and displayed
average size of 370 nm. They were tested as oral DDSs, using the model compound FD4.
It was found that when the drug was encapsulated in the more mucoadhesive NP type
(the preactivated ones), it exhibited higher oral bioavailability than that enclosed in the less
mucoadhesive ones [116]. Another example for this methodology is the preparation of a
surface-modified nanostructured lipid carrier (NLC). First, the preparation of curcumin-
loaded NLC was conducted by the melt emulsification technique, leading to a negatively
charged NLC. They were later surface-modified by polyelectrolyte complex interaction
with the thiomer CTS–NAC, leading to the ophthalmic coated formulation [125].
This method can be extended to the design of ionic complexes in which three different
macromolecules are involved: positively charged polymetformin-based NPs (loaded with
DOX), the negatively charged plasmid-encoding IL-12 gene, and a thiolated HA, as will be
discussed below [136].
The stability of the nanocomplexes formed by oppositely charged macromolecules
can be ensured by the appliance of a bonus intraparticle interaction; for example, by
means of the addition of small ions such as TPP, or the formation of disulfide bridges.
Thus, nanosuspensions loaded with the antituberculosis drug isoniazid were obtained by
polyelectrolyte complex formation between thiolated CTS–TGA and HA, using sodium-
tripolyphosphate (TPP) as an extra crosslinker [23]. This methodology is equivalent to that
reported for the development of polyelectrolyte complexes of thiomalyl CTS and insulin
for the oral delivery of the latter, in which TPP played a similar role [24].
Taking advantage of the use of thiolated polymers, the stabilization of polyelectrolyte
complexes can be boosted by the formation of disulfide linkages, generally exerted by
air-mediated oxidation of thiol groups at neutral or slightly basic pHs. An example for this
approach is the formulation of a stable polyelectrolyte complex of carboxymethyl(sulfate)-
CTS-4-thiobutylamidine and the basic fibroblast growth factor (dFGF). At pH 7.4, in the
presence of oxygen, the thiol groups from the CTS-based thiomer were easily oxidized to
disulfide bonds, adding stability to the NPs by forming an in situ crosslinked structure [30].
Similarly, thiolated glycol CTS can form stable nanoparticles with poly-siRNA through
charge–charge interactions and self-crosslink via disulfide bond formation after incubation
in HEPES buffer (pH 8.0) for 1 h at 37 ◦C. This structure provided sufficient stability from
nucleases while still allowing for mono-siRNA release in the cytosol upon systemic delivery
of poly-siRNA [122,124].
A triple interaction has been reported in NPs prepared from HA–SH. The thiomer
formed a polyelectrolyte complex poly-siRNA, which was stabilized by the addition of
calcium phosphate and disulfide bonds produced by thiol oxidation [31].
To conclude, HA- and CTS-based thiomer NPs are capable of encapsulating small
and biomacromolecular APIs involved in anticancer therapy with efficiency, mainly by
means of ionic gelation and polyelectrolyte complex formation. These two strategies can
be combined with each other and with disulfide bond formation to lead to stable and
reduction responsive drug-loaded NPs.
5. Thiomer Conjugates in Anticancer Therapy
5.1. Thiomer-Based Conjugates for Taxanes and Other Anticancer API Administration
Taxanes are common chemotherapeutic agents used for the treatment of cancers that
form a solid discrete mass (known as solid tumors), such as prostate or breast cancer.
They are obtained by processing the bark of some taxa of yew trees; for instance, the
most clinically relevant taxanes, which are paclitaxel (PTX, commercialized under the
brand Taxol®) and docetaxel (DTX, sold under the brand Taxotere®), can be isolated when
harvesting the bark of Taxus brevifolia (Pacific yew tree) [37] and that of Taxus baccata
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(European yew tree) [27], respectively (Figure 10). Nonetheless, today the obtention of
these molecules has been refined by the development of semisynthetic or even totally
synthetic chemical routes of production, such as the one described by Baloglu et al. for
paclitaxel from baccatin III [142]. This is very relevant for the development of these drugs
in the clinical field, considering that large-scale extraction of ingredients straight from the
forest may be very detrimental to the environment [142]. In this sense, it is obvious that
any substance that can be obtained by greener and more environmentally friendly methods
will more probably succeed in the long run (due to more availability, less economical costs,
better preservation of the environment, etc.) than any other that can only be isolated from
natural resources.
Figure 10. Chemical structures of paclitaxel, docetaxel, and 10-deacetylbaccatin, the building block
for their semisynthesis.
The use of these compounds in hematopoietic and lymphoid malignancies has not
been fully exploited and is not very widespread yet, remaining in the background compared
to other antineoplastic substances that exert their cytotoxicity through a very similar
mechanism, such as vincristine or vinblastine. Such mechanism of action is based on the
inhibition of microtubular depolymerization [27], with which the compound manages
to stop the division of tumor cells during the mitosis (M phase) of the cell cycle [143],
as shown in Figure 11. This is because the mitotic spindle (made of microtubules), and
more specifically microtubule reconfiguration, is essential during chromosome segregation.
Therefore, by inducing its failure, cancer cells undergo mitotic catastrophe and perish [144].
Even though PTX has been reported to be effective when used in tumors previously
characterized as refractory to conventional chemotherapy [145], some studies show that
DTX has about twice the cytotoxic effect of paclitaxel on tumor cells [146]. In any case, both
substances have demonstrated to be very promising among those found in the pharma-
copoeia of anticancer therapy. However, they are usually associated with serious adverse
effects when administered to patients, generally as injectable dosages [147]. For example,
paclitaxel needs to be mixed with Cremophor EL® (polyoxyl 35 hydrogenated castor oil,
a rather toxic molecule) and anhydrous ethanol in order to enhance its solubility to an
adequate level for intravenous administration [37]. As can be expected, this complex
formulation does not work as an inert vehicle; in fact, it triggers a wide range of biological
effects, some of which have important clinical implications, including severe anaphylactoid
hypersensitivity reactions, hyperlipidemia, abnormal lipoprotein patterns, aggregation of
erythrocytes, and peripheral neuropathy [147]. Other studies have shown that it can also
cause neurotoxicity, nephrotoxicity, and alterations of the endothelium and the vascular
muscles, leading to vasodilatation, labored breathing, lethargy, and hypotension [148].
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Figure 11. Mechanism of action of taxanes. Paclitaxel and docetaxel can bind microtubules during
the M phase of the cell cycle, therefore blocking their depolymerization. By doing so, they interfere
with the function of the spindle apparatus, so chromosomes are unable to move to the opposite sides
of the dividing cells structures during anaphase.
Moreover, these microtubule-targeting agents also present limited oral bioavailability,
which is an aspect that restricts their clinical use in cancer treatment [149]. This is a
major issue to be solved, considering their potential as a chemotherapeutic agent. Thus,
some groups have been investigating about the possibility of protecting these taxanes in
novel formulations that could allow oral administration [13,27,37,94,148,150,151]. This
might solve some of the problems associated with the parenteral injection of paclitaxel or
docetaxel, probably erasing the need of mixing it with such toxic surfactants, thus reducing
their systemic adverse effects.
One of these new approaches involves the administration of taxanes via such NPs
as, for example, those with a core made of PMMA and coated with thiolated CTS [37].
This formulation has been tested for both paclitaxel [37] and docetaxel [27] on colon and
breast cancer cells. The chitosan used in this study, which was subsequently thiolated, was
low-molecular-weight chitosan, obtained by prior degradation of commercial medium-
molecular-weight chitosan with NaNO2 [27,37]. The use of thiolated chitosan coatings,
compared to chitosan-based ones, has been proved to be very beneficial to the oral ad-
ministration of these taxane-loaded NPs, since the functionalization of the polymer with
thiol groups has ameliorated mucoadhesiveness up to 140 times [150]. In fact, thiolation of
biopolymers is, so far, one the most widely used strategies to enhance mucoadhesion [133].
This is essential when considering oral administration, because one of the main goals for the
drug-loaded NPs is to remain anchored to the mucus layer as much time as possible, from
which the taxanes will be taken up by the epithelial cells eventually. Free thiol groups from
the thiomer will not only interact with the cysteine-rich subdomains found in mucins [152]
(facilitating mucoadhesion), but also among the thiomer chains themselves. The latter
will result in the formation of disulfide bonds inside the coating of the NPs, which has
been proved to occur in a time-dependent and controllable manner [13]. In a nutshell, a
highly cohesive polymer network can be produced thanks to this stable crosslinking [13],
which serves as extra protection when administering the loaded compound. Apart from
this, the fact that CTS is a cationic polymer (zeta potentials of the NPs were proved to be
positive [27,37]) adds to the attaching forces participating to mucoadhesiveness; in this
case, electrostatic interactions will also have a role in anchoring the NPs to the mucus layer
of the intestine due to the anionic nature of the mucus.
Furthermore, the CTS coating can act as a chelant agent for metallic bivalent ions
needed for some intestinal enzymes to function, such as aminopeptidase N and chy-
motrypsin, which can be involved in the deactivating of the therapeutics molecules [13,27].
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Thus, by blocking the degrading activity of these enzymes, the successful intestinal uptake
for the taxanes will be boosted, and hence, their half-life increased when administered
orally. Finally, another relevant aspect that should be highlighted is the improved per-
meation of drugs through the gastrointestinal tract in the presence of thiolated polymers.
Thiomers have demonstrated their ability to open tight junctions between epithelial cells
by means of their thiol moieties, groups that are capable of inhibiting the protein tyrosine
phosphatase, responsible for the closing process of such tight junctions [94]. Therefore,
the access of the drugs to the systemic circulation will be promoted, with a concomitant
improvement in the bioavailability of the therapeutic agent, thus it makes sense to refer
to these materials as permeation enhancers. This process is known to be mediated by
glutathione [94].
The studies that we have referenced in this section demonstrate the obvious potential
that CTS-coated NPs have in the biomedical field. Focusing now on the pharmacokinetics
and pharmacodynamics of these formulations, the studies that investigated them gave
rather clear proof of high encapsulation efficiency of the nanoparticles (∼90% for DTX [27]
and ∼98% at maximum for paclitaxel [37]), sustained released of the drug after a burst at
the beginning [27,37], increased transportation of the drug and great cellular uptake [27,37],
selective cytotoxic effect in cancer cells [27,37], biodegradability, and biocompatibility.
Other possibilities have also been tackled regarding the use of CTS as part of taxane-
loaded NPs, which serve as carriers for the drug in oral administration. One study ap-
proached this issue by creating NPs made of the random copolymer poly(lactide-co-ε-
caprolactone)-D-α-tocopheryl polyethylene glycol 1000 succinate (PLA–PCL–TPGS) and
then modified superficially with thiolated chitosan [151]. These were shown to be poten-
tially successful for the delivery of docetaxel to lung cancer cells [151]. PLA–PCL was used
to strengthen the polymer, while TPGS was intended to make the loaded compound more
permeable though biological membranes [151]; in fact, previous studies showed that this
derivative of vitamin E can enhance absorption of drugs by inhibiting the efflux pumps in
cancer cells (such as P-gp) while being nontoxic to healthy ones [153,154].
Just as the ones presented before, this study concluded with the same ideas: the NPs
showed good cellular uptake and drug absorption (best results when they were modi-
fied with thiolated chitosan), sustained released, low systemic toxicity, biocompatibility,
biodegradability, protection from drug degradation in gut, reduction of multidrug resis-
tance (via blocking of P-gp), high encapsulation efficiency, and overall effectiveness [151].
Moreover, this work introduced a very interesting idea: thiolated chitosan per se has an
antitumor effect as well. It was observed that caspase-3-dependet apoptosis was induced in
lung cells when exposed to chitosan [151]. Therefore, this biopolymer itself may be acting
synergistically with the loaded anticancer agents, which gives it another advantage, now
not just working as a plain carrier but also contributing to cancer cell mortality.
Hyaluronic acid (HA) has also been utilized in some works as a vehicle for taxanes;
for instance, Zhang et al. designed nanoparticles based on the conjugation of HA with
octadecylamine (OA) [155]. The resulting complex was then functionalized with NAC
with the objective of improving oral PTX delivery. In this way, these NPs were tested
and compared with PTX-loaded nonfunctionalized HA–OA NPs, and also with Taxol®.
Encapsulation efficiency was demonstrated to be optimal (∼93%) for the first ones, while
they also showed higher cellular uptake by endocytosis and better pharmacokinetic profile
than the rest [155]. Therefore, the NAC functionalization was proven to be an effective
permeation enhancer for drugs administered orally, since its thiol groups allow the NPs to
exert considerably better adhesiveness to the intestinal mucous surface. Figure 12 shows a
schematic illustration of the procedure followed in this study.
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Figure 12. Summary of the assembly of PTX-loaded micelles (PTX–NHOA) based on an N-
acetylcysteine-modified hyaluronic acid–octadecylamine conjugate. Improved oral paclitaxel delivery
through the intestinal mucus layer was achieved. Reprinted with permission from [155] (Copyright
2019 Elsevier Editorial).
Apart from these two major polysaccharides, other interesting approaches have also
been made. For example, Föger and coworkers carried out some in vivo investigations to
evaluate a novel oral formulation of PTX based on thiolated polycarbophil [156]. Polycar-
bophil is the USP/NF compendial name of a family of polyacrylic acids loosely crosslinked
with divinyl glycol with broad applications in biomedical and pharmaceutical fields [157],
including as a laxative to treat constipation. When thiolated, it was demonstrated that
P-gp inhibition was enhanced significantly, thus reducing tumor growth in mammary-
cancer-induced rats more efficiently than intravenous paclitaxel [156]. Thiolated oligo(p-
phenylenevinylene) (OPV–SH) has also been tested as a potential carrier for PTX into cancer
cells by Zhou and coworkers [158]. In that case, a PTX–OPV conjugate was synthesized
with the intention of reversing drug resistance by facilitating PTX delivery into the cells.
OPV was chosen because of its biocompatibility and low cytotoxicity to normal cells. This
work focused on taking advantage of the abundance of reactive oxygen species (ROS)
inside the tumor cells to motivate crosslinking of the conjugate once it arrived at such cells.
This mechanism is what they called “chemical locking”, and it was proven to successfully
block tumor growth in xenotransplanted mice [158].
Levit et al. also recently demonstrated that NPs consisting of biodegradable poly(amino
acid) and poly(2-deoxy-2-methacrylamido-D-glucose) (PMAG) can function as a reliable
delivery system for paclitaxel in glutathione-rich conditions [159]. Great results were
achieved when evaluated in A549 (human lung carcinoma cells) and MCF-7 (human breast
adenocarcinoma) cells. Furthermore, thiolated sodium alginate has also shown to be
promising, as proved by Chiu et al. [160]. This group synthesized disulfide-crosslinked
NPs from the aforementioned material, and then coated them with fluorescein-labelled
wheat germ agglutinin. The resulting NPs exerted favorable results for the delivery of
docetaxel to human colon cancer cells, thus introducing this new polymer to the broad
range of suitable materials for NP-dependent anticancer therapy.
Finally, dextran has also been used as part of thiolated carriers for hydrophobic thera-
peutics; for instance, as part of a hydrogel resulting from conjugation between thiolated
human serum albumin and dextran. This albumin-based dextran conjugate demonstrated a
broad range of potential biomedical applications as an efficient drug-delivery system [161].
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Some studies with thiomers that focus on the delivery of other APIs apart from tax-
anes have also been published. These approaches can be considered as new horizons
and references when tackling new formulations for the administration of taxanes. For
instance, thiolated chitosan copolymer (functionalized with NAC) was utilized to coat
curcumin-loaded nanostructured lipid carriers (NLCs) in an investigation carried out by
Liu et al. The introduction of this thiol-rich coating allowed this formulation to exert better
properties than the uncoated homologues, such as significantly enhanced transcorneal
penetration and more sustained release of the loaded compound [125]. These advantages
prove that thiomers may not only be useful for oral administration, but also for other
approaches such as ophthalmic drug application. In fact, some controlled clinical trials
have been performed to evaluate the benefits of thiolated polymers when used for ocular
pathologies, such as those designed by Schmidl et al. [162]. They aimed to study the
effect of CTS–NAC eye drops on tear film thickness in patients with dry eye syndrome.
Results showed that the corneal status significantly improved in more than 60% of patients,
with most of them starting to show beneficial results as early as 10 min after a single
instillation of CTS–NAC [162]. This polymer has also been tested, along with CTS–NAP
(CTS–N-acetylpenicillamine), as a platform to deliver doxorubicin (DOX) and antisense
oligonucleotides (ASOND) targeting EGFR, which is a transmembrane receptor overex-
pressed in most of the cases of breast cancer with poor prognosis [114]. When evaluated
on T47D cells (human breast epithelial tumor cells), these NPs showed similar properties
as the ones stated before, such as sustained release, good encapsulation efficiency, and
stability (especially those carrying ASOND), so the clinical potential of this formulation
is obvious.
Continuing, thiolated hexanoyl glycol CTS (SH–HG–CTS) has also been investigated
in the biomedical area as a plausible drug-delivery system. From the studies with such
material, that of Cho et al. can be highlighted: this group synthesized SH–HG–CTS
by first chemically modifying glycol CTS with hexanoic anhydride, and then introduc-
ing thiol groups by adding activated 3-mercaptopropionic acid [113]. SH–HG–CTS was
demonstrated to have optimal thermo-gelling, mucoadhesive, and cytotoxic profiles, so
further research should be conducted in order to possibly include this novel material in
drug-delivery formulations.
Other works explore more complex formulations for NPs, such as the one developed
by Sun and coworkers. These investigators prepared a nanosystem for the codelivery of
DOX and plasmid encoding IL-12 gene (pIL-12), so that it could be used as a combination
therapeutic method for metastatic breast cancer [136]. IL-12 has been reported to function
as a cytokine that promotes antitumor activity, with immunomodulating, antiangiogenic,
and antimetastatic actions that facilitate the suppression of tumor growth. The approach
tackled by this group was based on DOX + IL-12-loaded polymetformin NPs, which were
later completed with the addition of thiolated hyaluronic acid for better properties. These
so-called micelleplexes exerted prolonged circulation in blood, efficient accumulation in
tumors, excellent pIL-12 transfection, and sustained DOX release [136], so they hold great
promise for ameliorating current chemo–gene combination therapies.
It is also interesting to mention that Bayat et al. explored how the functionalization
of thiolated nanoparticles can affect drug delivery for childhood acute lymphoblastic
leukemia (ALL), a study that had not been conducted before, even though ALL is the
most common infant malignancy [163]. So far, most of the investigations regarding the
use of nanoparticles for anticancer therapy have focused on treating solid tumors, so
the fact that this group has developed an approach for hematological cancer is, by itself,
worth mentioning. In this case, Bayat and coworkers demonstrate that NPs based on
star polymers made out of poly(oligoethylene glycol methyl ether acrylate) (POEGA), or
POEGA and poly(diethylene glycol ethyl ether acrylate) (PDEGA), can be efficiently used
for the objective previously stated, with the latter being more successful [163]. These star
polymers were also thiolated and functionalized with several very short ethoxy repeating
units in the outermost part.
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Overall, it was demonstrated that thiolated and functionalized star polymers can
be used to safely improve cellular association and uptake of diverse APIs in childhood
ALL, opening a broad range of new opportunities for boosting thiomers’ relevance in
the treatment of blood cancers. In fact, some variants of these materials have already
been developed for the delivery of siRNA and other chemical compounds involved in
anticancer therapy (such as doxorubicin), as well as for magnetic resonance imaging
contrast agents [163].
A brief list of selected studies regarding efficient taxane and other APIs delivery in
cancer therapy (conducted with thiomer-based formulations) is summarized in Table 9.
The results presented herein show the advantages of thiomers, such as those based on
CTS and HA, in the effective and selective delivery of anticancer drugs to cells in solid
tumors. In fact, these agents have become a pertinent tool in cancer care for the treatment
of both nonadvanced disease and late-stage disease [164]. Nevertheless, more investigation
is still needed, especially that regarding the testing of these novel formulation in human
beings. They have been demonstrated to be potentially useful in the clinical field, not only
in the delivery of chemotherapeutics through the gastrointestinal tract, but also in the oral
administration of other APIs such as insulin [165,166]; even in this situation, most of the
research work done so far could only be included in what we called the preclinical phase.
Table 9. Summary of selected studies regarding efficient delivery of taxanes and other APIs in cancer therapy, conducted
with thiomer-based formulations.
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MCF-7 (breast carcinoma), HCT-116
(human colon cancer), SKOV-3




PLGA and OCTS b,c Nanoparticles CHC and CTX U251 and SW1088 (glioma cell lines) [80]
Thiolated
carboxymethyl chitosan c Nanoparticles Methotrexate HeLa (cervical cancer) cells [25]
POEGA + PDEGA
(star polymers) Nanoparticles -
Jurkat (T-ALL) and Nalm-6 (B-ALL)
cancer cell lines [163]
a This work did not use a thiolated polymer per se for the synthesis of nanoparticles, but involved a polymer linked with disulfide bonds
to thiolated human serum albumin. b This work did not use a thiolated polymer per se for the synthesis of nanoparticles but involved
a PEG crosslinker to link the loaded compounds to the polymer via Michael reaction. c These works correspond to approaches that
were not directly applied to taxanes, but can be considered as new horizons and references when tackling newer formulations for the
administration of these APIs. CHC: alpha-cyano-4-hydroxycinnamic acid; CTS: chitosan; CTX: cetuximab; GSH: reduced glutathione;
HA–OA: hyaluronic acid–octadecylamine; IL-12: interleukin 12; NAC: N-acetylcysteine; NAP: N-acetylpenicillamine; OCTS: oligomeric
chitosan; OPV: oligo(p-phenylenevinylene); PDEGA: poly(diethylene glycol ethyl ether acrylate); PEG: polyethylenge glycol; PLA–PCL–
TPGS: poly(lactide-co-ε-caprolactone)-D-α-tocopheryl polyethylene glycol 1000 succinate; PLGA: poly(lactic-co-glycolic acid); PMAG:
poly(2-deoxy-2-methacrylamido-D-glucose); PMMA: poly(methyl methacrylate); POEGA: poly(oligoethylene glycol methyl ether acrylate).
5.2. Thiomer-Based Conjugates for siRNA Administration
Interfering RNAs (iRNAs) are RNA molecules of 20–25 nucleotides of length whose
structure makes them able to participate in a biological route known as ribo-interference or
RNA-mediated interference [168]. Several studies have shown that this ancient process
(dating evolutionarily even before the divergence of plants and animals [169]) can be con-
sidered as the oldest and most ubiquitous antiviral system [169]. In this way, several types
of iRNAs have been investigated, but we will focus on small interfering RNAs (siRNA).
The main goal for which cells use these particles is post-transcriptional gene silencing
or, more particularly, gene downregulation, by targeting and destroying its messenger
RNA (mRNA). In fact, the discovery of this cellular mechanism was so relevant that it
made investigators Mello and Fire Nobel laureates in Medicine or Physiology in 2006.
Structurally, siRNAs are double-stranded molecules that are synthesized by the cell in
such a way that the sequence of one of its strands is complementary to that of the target
messenger RNA. Actually, the first biological product that appears in the cell cytoplasm is
a longer double-stranded piece of iRNA that is later cut into proper siRNAs by an enzyme
called Dicer [170], as shown in Figure 13. Afterward, these fragments are captured by
another enzyme, RNA-induced silencing complex (RISC), which will separate both strands
and degrade the passenger strand; that is, the one with the same sequence as the target
mRNA [170]. By doing this, RISC will incorporate the remaining strands (the antisense
one) as if it was a cargo, and use it as a guide to identify the target mRNA via sequence
complementarity [170]. Finally, once the correct mRNAs are recognized, RISC is able to
cleave them, which lowers the amount of material that can be traduced, thus reducing the
expression of the corresponding gene.
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Figure 13. Basic functioning of RISC-based gene-silencing system.
The clinical potential shown by this natural gene-suppression technique is enor-
mous, giving that it occurs naturally during cell maturation, and is very selective and
efficient [170]. In fact, as of 2013, around 22 iRNA-based therapeutic formulations were be-
ing investigated regarding the treatment of hereditary pathologies, viral infections, cancer,
and other diseases that lack drug-based therapeutic options so far [170]. Moreover, it has
been proved to be a very useful tool not only in the clinical field, but also in the biomedical
and preclinical ones, since it allows the replication of pathologies in which genes are poorly
expressed (knock-down animal models).
Nowadays, after discovering the possible usefulness of siRNAs in human therapy, in-
vestigations of delivery techniques of such molecules have boomed; namely, consideration
of how fragile they are. For the iRNA machinery to function, siRNA molecules must be
efficiently transported to the interior of the target cells while being protected from enzyme
degradation and other damaging processes at the same time (especially when administered
orally) [140,170].
Currently, there are some synthetic, nonviral delivery agents for siRNA that are on the
rise for showing to be the most promising, among which mainly lipid-based formulations
are found [140]. Some cationic molecules (including several polymers) have been used
in successfully transporting siRNA in mammal cells while also avoiding major toxic
effects [140]. In any case, direct conjugation of the delivery agents has been proven to
facilitate both selectivity and efficacy in the delivery process, and also reduce the potential
immune stimulation against the double-stranded RNAs (which is undesirable). As an
example of the first aspect, a study conducted by Soutschek et al. demonstrated that
cholesterol-bound siRNA resulted in the efficient silencing of the apoB mRNA specifically
in liver and jejunum cells [140,171]. Moving on to the second idea, it has been suggested
that siRNA can stimulate TLR receptors in dendritic cells if endocytosed and processed
into their constituent oligonucleotides [172], so it poses a risk to the patient if their immune
system were to react violently against it (some off-target gene effects can be associated with
this inflammatory response). With this idea in mind, some groups explored the option
of incorporating 2’-O-methyl-modified uridine or guanosine residues into the interfering
RNAs to avoid that immune stimulation, and some promising results were obtained [173].
Having introduced the main aspects of the status quo of siRNA in the clinical area,
the attention will now be focused on thiolated polymers as an efficient delivery agent.
J.Y. Yhee et al. studied the formation of intravenous-delivered NPs from self-crosslinked
thiolated glycol chitosan as a way to effectively transport siRNA to cancer cells [124]. The
main purpose of using this technique was to make tumor cells more sensitive to chemical
chemotherapeutics by blocking the efflux pump [124]. Therefore, the administration of
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these NPs is intended to accompany dosages of other therapeutic elements: the siRNAs
is targeted against P-glycoprotein mRNA, which acts as an efflux pump in cancer cells
and participates in the clearance of the administered chemical compounds. Moreover, the
selectivity of NPs uptake in cancer cells is improved naturally by the EPR effect [124].
With this in mind, if the expression of this kind of protein is downregulated, tumor
cells will be indirectly made less resistant to proper drugs; that is, overcoming drug resis-
tance in cancer [124]. That is why this is thought to be a possible adjuvant or supplementary
therapy to what already has been achieved. Some of the obvious benefits of this medication
would be that subtherapeutical doses of chemotherapeutics could now be efficient against
certain tumors [124]; if the dosage is reduced, so will the systemic effects associated with
the toxicity of the compound. So, even though it is not thought to be a monotherapeutic
treatment, it is a promising tool in the oncology field.
As stated previously, CTS was functionalized with thiol groups; nonetheless, it was
not the only modification that has been conducted. It has been demonstrated that certain
modifications of siRNA could make it more avid to binding to its corresponding carrier, thus
improving the stability of the formulation [124]. In particular, reducible poly-siRNA has
been proposed as a possible solution for low delivery efficiency of these molecules [100,174].
The formation of this poly-siRNA would be plausible via thiolation of the 5′-end of the two
strands of each RNA fragment, which would allow these double-stranded RNA molecules
to not only conjugate among themselves, but also with the thiolated polymer, thus forming
an extensive network of interconnected disulfide links that could easily be cleaved in
a reductive ambiance, like the one found in the cellular interior [100,122,124,174]. This
glutathione-rich compartment would allow disulfide links to break, hence disintegrating
NPs once captured by the target cells and efficiently delivering monomeric siRNA to the
corresponding machinery in cellular cytosol [100]. Moreover, if cationic thiolated polymers
are used, such as CTS-based thiomers, electrostatic interactions are also utilized: the NP
network is further strengthened because of the net negative charge exhibited by poly-
siRNA, so it can be successfully incorporated into carriers with cationic charge density,
such as thiolated CTS derivatives [124].
For example, thiolated glycol chitosan–poly-siRNA NPs were shown to be a useful
tool to prevent enzyme degradation of the ribonucleic acids (if injected into the bloodstream
alone, its half-life was significantly shortened) and adequately release the molecules when
the conditions favored the cleavage of the disulfide bridges [124]. Furthermore, the system
exhibited excellent stability in serum, a better pharmacological profile than the chemical
adjuvant alone, and no unintended immune stimulation. In conclusion, the results showed
that the P-gp downregulation was quantitatively achieved (–62% of P-gp expression in
cancer cells [124]), which consequently led to a greater concentration of the adjuvant
chemotherapeutic inside the tumor cells. Figure 14 represents a schematic illustration of
the procedure followed in this study.
The synthesis of NPs based on thiolated glycol chitosan and poly-siRNA was an
approach also tackled by Lee et al. in 2011. Here, they specified that NPs were able
to form thanks to simultaneous self-crosslinking and charge–charge interactions [122].
Eventually, these investigators came to similar conclusions as those presented previously:
this nanostructure allowed tumor-targeted mono-siRNA release, which could be taken
by cells efficiently for optimal gene silencing. These experiments were carried out in vivo
by injecting the preparation into tumor-bearing mice, and the targeted gene was that
expressing the vascular endothelial growth factor (VEGF). Consequently, results showed
that angiogenesis in tumors treated with small amounts of siRNA was significantly reduced,
leading to a quite successful conclusion [122].
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Figure 14. Formation, intracellular delivery, and mechanism of action of thiolated glycol chitosan–
nanoparticles containing siRNA against P-gp. (a) Thiolation of siRNA and glycol chitosan. (b)
Formation of NPs. (c) Glutathione-dependent siRNA delivery in cells. Reprinted with permission
from [124] (Copyright 2015 Elsevier Editorial).
It is evident that chemo–siRNA combination therapy shall be considered as a future
option to significantly lower tumor growth rates while avoiding major signs of excessive
systemic toxicity; in fact, this is an investigational approach already in the making for cases
such as triple-negative breast cancer [175].
Similar studies have been conducted by other groups that intended to exploit the
potential of siRNA, such as that of Work and coworkers [176]. This specific example ex-
plored a novel formulation for the delivery of siRNA based on an N-(2-hydroxypropyl)
methacrylamide-s-N-(3-aminopropyl)methacrylamide (HPMAm-s-AMPAm) copolymer,
which was synthesized via RAFT-polymerization [176]. HPMAm was the main compo-
nent (90 mol %) of the copolymer described by the authors, because it tends not to be
immunogenic and it is soluble in water-based solvents [176]. In a similar fashion to what
already has been described, this approach permitted satisfactory poly-siRNA cleavage in
glutathione-rich conditions. In this case, incorporation of folate into the formulation was
also attempted to achieve targeting of the system toward cancer cells, as it is a natural
moiety that is able to target these cells [176]. By doing that, enhanced specificity regarding
the site of action of the NPs was expected [177]. In this case, no thiolated polymer was
used, but it is an approach that can easily serve as the basis for the synthesis of new
HPMAm-s-AMPAm-based thiomers.
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Moreover, the strategy tackled by Varkouhi et al. is also worth mentioning. It was
based on the synthesis of another nonviral vector for nucleic acid delivery, in this case in
the form of polyplexes from thiolated N,N,N-trimethylated chitosan (thiolated TMC) [178].
By generating this derivative of CTS, the investigators managed to improve safety, effec-
tiveness, and solubility in aqueous solvents at neutral pH. Several trials were carried out
comparing thiolated TMC to its unthiolated homologue, and also to the lipidic transfection
agent Lipofectamine. In most of the experiment, the thiolated TMC demonstrated to be
markedly better regarding gene-silencing activity, protection against degrading nucleases,
release kinetics, cellular uptake, and overall clinical profile [178].
Additionally, this group studied the influence of HA as both a prevalent macro-
molecule in the extracellular fluids and as part of the copolymer forming the NPs. In this
sense, there is evidence that supports the fact that hyaluronic acid can be considered as a
double-edged sword. On the one hand, the gene-silencing efficiency of these polyplexes
has been shown to be significantly reduced in the presence of hyaluronic acid, and this
is something to take into account, since this glycosaminoglycan is rather abundant in
our connective, epithelial, and neural tissue. For instance, this negative connotation was
evaluated in a study conducted by Van de Wetering et al., in which they figured out that
transfection efficiency can be diminished up to fourfold [179]. Therefore, it is not surprising
that the study inferred that hyaluronic acid may act as a competitor molecule with the NPs.
Apart from this, serum proteins might also play an important role in lowering the cellular
uptake of NPs [178].
On the other hand, if incorporated into the NPs themselves, HA has demonstrated
to add stability to the overall structure of the NPs; Varkouhi et al. tested this hypothesis
by synthesizing NPs from both thiolated and nonthiolated TMC in combination with
either thiolated or nonthiolated HA [178]. From the four resulting conjugates, the one
that showed the highest gene-suppression activity was the mixture of thiolated TMC and
thiolated HA, probably because the stability of the polyplex was enhanced thanks to the
formation of more disulfide bonds between both types of polymers [178]. Furthermore,
other works used thiolated HA in a similar fashion to what was presented in the section
on taxanes; that is, as a detachable shell covering a more consistent core. An example
of this was developed by Yin and coworkers using octyl-modified polyethyleneimine
containing disulfide linkages (PSR) as the core of the NPs [180]. In this case, the thiolated
HA covering not only served as protection for the drug-loaded cores, but it also allowed
a more selective tumor-targeting thanks to the fact that HA is a molecule recognized by
cluster of differentiation 44 (CD44), which is usually overexpressed in some neoplasms.
This system was proven to effectively be able to codeliver hydrophobic chemotherapeutics
and hydrophilic siRNA, maximizing synergistic antitumor efficacy via a GSH-mediated
release of both components [180].
Another example involving thiolated HA is that presented by Zhou et al. In this case,
cross-linked thiolated HA was used to form an anionic outer shell to protect, stabilize, and
optimize the siRNA-loaded core. This core was not designed the same way as the previous
example; instead, it was synthesized so that the siRNA would be capable of forming the
core without using other polymers. These investigators managed to do this by stabilizing
siRNA with calcium phosphate as a core inside the thiolated HA shell [31]. The consequent
studies with intravenous injection of the formulation demonstrated excellent transfection
efficiency, selective release of siRNA into the cytosol (via GSH-dependent dismantling and
successful endosomal escape), no apparent toxicity, and also around 80% gene-suppressing
efficacy in vitro for both luciferase and B-cell lymphoma 2 (Bcl-2) genes [31]. Bcl-2 is part
of a family of regulator proteins that modulate cell death; in particular, it plays a relevant
role in inhibiting the actions of proapoptotic proteins (thus allowing cells to survive). That
is why its silencing in cancer cells will lower tumor growth, because it will be promoting
apoptosis of those cells.
Three more studies can be highlighted as relevant examples of successful delivery
systems for siRNA. The first one was thought to be an immunotherapy method to boost
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the natural ability of the human immune system to destroy cancer cells. In fact, similar
approaches (but using antibodies instead of siRNA) tackled by Allison and Honjo were
so revolutionary and had so much impact that they resulted in the concession of the
2018 Nobel Prize in Physiology and Medicine to the abovementioned investigators. As
immunotherapeutic agents are on the rise, Bastaki et al. contributed to the field with
their experiments in the delivery of siRNAs to silence programmed cell death-ligand 1
(PD-L1) and signal transducer and activator of transcription-3 (STAT-3) genes [181]. By
doing so, they designed TMC and thiolated chitosan NPs to hold the desired siRNA,
as shown in Figure 15. Moreover, the NPs were completed by conjugation with HIV-1-
derived TAT peptide and HA. The in vivo experiments shed light on promising results
regarding significant downregulation of PD-L1 and STAT-3 genes. Consequently, important
restriction of tumor growth was achieved: proliferation, migration, and angiogenesis of
breast and melanoma cancer cells lines were strikingly lowered [181].
Second, in 2014 Muthiah and coworkers registered an NP-based formulation for
efficient anticancer gene therapy via silencing of serine-threonine protein kinase Akt1′s
gene. This protein has been reported to participate in biochemical pathways participating
in the suppression of apoptosis, so the hypothesis suggested by this investigation group
is that inhibiting its action should promote an antiproliferative response. In this case,
polyethylenimine (PEI) was thiolated in order to synthesize the NPs responsible for the
delivery of also-thiolated siRNA [182]. Disulfide bonds between the polymer and the
siRNA ensured stability of the formulation. The antitumor effects of these NPs were tested
using mouse colon cancer cells and in vivo mouse tumor models, in which it was proven
that cellular uptake was enhanced and neoplasm proliferation was reduced via effective
downregulation of Akt1 [182].
Last but not least, thiolated gelatin has been used for the same purpose as well [183].
Thus, siRNA gelatin NPs were administered to tumor-bearing mice to evaluate the pharma-
cological effects of this approach in vivo. The authors demonstrated that thiolated gelatin
effectively protects siRNA molecules from degradation while simultaneously allowing
their delivery to target cells in reductive conditions. It was concluded that these NPs can
motivate significant gene silencing in vivo without remarkable toxicity [183].
A brief list of selected studies regarding efficient anticancer siRNA delivery (conducted
with thiomer-based formulations) is displayed in Table 10. Summarizing everything stated,
it is evident that these novel siRNA-based strategies have great potential for cancer treat-
ments. They may be used as adjuvant therapy to the administration of chemotherapeutics
in order to reduce the doses needed, and thus the associated toxicity. More clinical trials
are needed to ensure the safety and effectiveness of these, and therefore to make possible
their commercialization and usage in lieu of other more traditional and harsh therapeutic
treatments. Thiomers have demonstrated to be an optimal delivery system for siRNA, but
again, more studies need to be conducted to enable their commercialization as safe and
effective antitumor formulations.
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Figure 15. (a) Formation of siRNA-loaded TAT–HA–TMC–TC NPs. (b) Intracellular delivery and mechanism of action of
siRNA-loaded TAT–HA–TMC–TC NPs. Reprinted with permission from [181] (Copyright 2021 Elsevier Editorial).
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Table 10. Summary of studies regarding efficient anticancer siRNA delivery conducted with thiomer-based formulations.
Thiomer Formulation Loaded Compound Cancer Cells Studied InVitro Ref.





Thiolated glycol CTS Nanoparticles VEGF siRNA
RFP-expressing B16F10
(murine melanoma) cells.




HPMAm-s-AMPAm a Multiconjugates siRNA and folate - [176]
Thiolated TMC (both
alone and with HA) Polyplexes siRNA
H1299 (human lung
cancer) cells [178]
Thiolated HA + PSR
Nanoparticles











calcium phosphate core +
thiolated hyaluronic
acid coating)




(thiolated chitosan + TMC









Thiolated PEI Nanoparticles Akt1 siRNA
CT-26 (mouse colon cancer)
cells. In vivo studies in
mouse tumor models
[182]
Thiolated gelatin Nanoparticles siRNA
RFP-expressing B16F10
(murine melanoma) cells.
In vivo studies in
tumor-bearing mice
[183]
a This work did not use a thiolated polymer for the generation of nanoparticles, but it is an approach that can easily serve as the basis
for the synthesis of new HPMAm-s-AMPAm-based thiomers. Bcl-2: B-cell lymphoma 2 gene; CTS: chitosan; HA: hyaluronic acid;
HPMAm-s-AMPAm: N-(2-hydroxypropyl)methacrylamide-s-N-(3-aminopropyl)methacrylamide; MDR: multidrug resistance gene; PD-L1:
programmed cell death-ligand 1; PEI: polyethylenimine; PSR: octyl-modified polyethyleneimine containing disulfide linkages; siRNA:
small interfering ribonucleic acid; STAT-3: signal transducer and activator of transcription-3; TMC: N,N,N-trimethylated chitosan; VEGF:
vascular endothelial growth factor.
6. Conclusions
In summary, attractive and reliable methods are available for preparing NPs from
CTS- and HA-based thiomers with smart properties for their applications in cancer ther-
apy, particularly NP formulations with taxanes and siRNA. The most interesting and
reliable synthetic methods available for preparing CTS- and HA-based thiomers have been
highlighted, with their advantages and drawbacks. The reported procedures could be
extended to other relevant natural or synthetic polyelectrolytes, with a consequent potential
boost in this research field. We anticipate that this work could inspire the development
of cutting-edge thiomer-based NPs with improved clear advantages in drug delivery for
cancer therapies, and with other therapeutical uses.
Author Contributions: Conceptualization, methodology, validation, formal analysis, project ad-
ministration, supervision, funding acquisition: M.-V.d.-P.; investigation, writing—original draft
preparation, writing—review and editing, R.G., M.-V.d.-P. All authors have read and agreed to the
published version of the manuscript.
Pharmaceutics 2021, 13, 854 40 of 48
Funding: The authors are grateful to have received financial support from Ministerio de Ciencia,
Innovación y Universidades (MICINN) of Spain (Grant MAT2016-77345-C3-2-P), and Junta de
Andalucía (Grant P12-FPM-1553).
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.









APIs Active pharmaceutical ingredients
ASOND Anti-sense oligonucleotides
Bcl-2 B-cell lymphoma 2


















EGFR Epidermal growth factor re-ceptor








HPMAM-s-AMPAM N (2 Hydroxypropyl)methacrylamide-s-N-(3-aminopropyl)methacrylamide
HSA Human serum albumin
i-PATAI Isopropyl (acetylthio)acetimidate
iRNAs Interfer-ing RNAs







Pharmaceutics 2021, 13, 854 41 of 48
MPPT 3-Methyl-1-phenylpyrazole-5-thiol
mRNA Messenger RNA
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